CN114948978A - Pharmaceutical composition and application thereof - Google Patents
Pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN114948978A CN114948978A CN202110215334.0A CN202110215334A CN114948978A CN 114948978 A CN114948978 A CN 114948978A CN 202110215334 A CN202110215334 A CN 202110215334A CN 114948978 A CN114948978 A CN 114948978A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- weight ratio
- ginsenoside
- notoginsenoside
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims abstract description 355
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 claims abstract description 285
- 229930183842 salvianolic acid Natural products 0.000 claims abstract description 285
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 35
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 210000000056 organ Anatomy 0.000 claims abstract description 13
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 7
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims abstract description 5
- 208000023589 ischemic disease Diseases 0.000 claims abstract description 5
- 208000014674 injury Diseases 0.000 claims abstract 2
- 229930189092 Notoginsenoside Natural products 0.000 claims description 200
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 155
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 142
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 140
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 140
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 136
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 136
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 136
- MGEVFIHLEFXNMC-MBOAKDCMSA-N (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6S)-6-[(2S)-2-[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-3-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1 MGEVFIHLEFXNMC-MBOAKDCMSA-N 0.000 claims description 120
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 107
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 105
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 claims description 95
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 94
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 claims description 74
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 73
- UJZQBMQZMKFSRV-RGKBJLTCSA-N (2s,3s)-4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 UJZQBMQZMKFSRV-RGKBJLTCSA-N 0.000 claims description 72
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 72
- UJZQBMQZMKFSRV-PHQFMFTGSA-N Lithospermic acid Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@@H](C(=O)O)[C@H](c3cc(O)c(O)cc3)Oc2c(O)cc1 UJZQBMQZMKFSRV-PHQFMFTGSA-N 0.000 claims description 72
- NFOCYHUCMXEHDG-UHFFFAOYSA-N Monomethyl lithospermate Natural products COC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 NFOCYHUCMXEHDG-UHFFFAOYSA-N 0.000 claims description 72
- CLZDRNKNWXDFQT-UHFFFAOYSA-N Salvianolic acid L Chemical compound C=1C=C(O)C(O)=CC=1C1C(C(=O)OC(CC=2C=C(O)C(O)=CC=2)C(O)=O)=CC2=CC=C(O)C(O)=C2C1C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 CLZDRNKNWXDFQT-UHFFFAOYSA-N 0.000 claims description 72
- YIILBLCUEGUPOW-GFXWHGLYSA-N salvianolic acid L Natural products OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)C2=Cc3ccc(O)c(O)c3[C@@H]([C@H]2c4ccc(O)c(O)c4)C(=O)[C@H](Cc5ccc(O)c(O)c5)C(=O)O YIILBLCUEGUPOW-GFXWHGLYSA-N 0.000 claims description 72
- SNKFFCBZYFGCQN-DUMGGQTMSA-N (2S)-2-[(E)-3-[(2R,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@@H](C(=O)O[C@@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1 SNKFFCBZYFGCQN-DUMGGQTMSA-N 0.000 claims description 70
- SOXUSBQFIOBYJU-VPIXDIMLSA-N (2r)-2-[(e)-3-[2-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-1-(3,4-dihydroxyphenyl)-3-oxoprop-1-en-2-yl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C(=C/C=1C=C(O)C(O)=CC=1)C(=O)O[C@H](CC=1C=C(O)C(O)=CC=1)C(O)=O)C1=CC=C(O)C(O)=C1 SOXUSBQFIOBYJU-VPIXDIMLSA-N 0.000 claims description 70
- AZOCLKLJIKZOLF-ZPOOTWMUSA-N (2r,3r)-2-[4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-hydroxyphenoxy]-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid Chemical compound C([C@@H](OC(=O)/C=C/C1=CC=C(C(=C1)O)O[C@H]([C@H](O)C=1C=C(O)C(O)=CC=1)C(O)=O)C(O)=O)C1=CC=C(O)C(O)=C1 AZOCLKLJIKZOLF-ZPOOTWMUSA-N 0.000 claims description 70
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 70
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 70
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 70
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 claims description 70
- HFTLCJIFEZUOCR-JKXXRSRDSA-N Isomelitric acid A Chemical compound C=1C=C(O)C(O\C(=C/C=2C=C(O)C(O)=CC=2)C(O)=O)=CC=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 HFTLCJIFEZUOCR-JKXXRSRDSA-N 0.000 claims description 70
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 70
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 70
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 70
- KFCMFABBVSIHTB-WUTVXBCWSA-N Salvianolic acid D Chemical compound OC(=O)CC1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C(O)=O)CC1=CC=C(O)C(O)=C1 KFCMFABBVSIHTB-WUTVXBCWSA-N 0.000 claims description 70
- UMPZKDHDIZUVTO-UHFFFAOYSA-N Salvianolic acid D Natural products Cc1ccc(C=CC(=O)OC(Cc2ccc(O)c(O)c2)C(=O)O)c(CC(=O)O)c1O UMPZKDHDIZUVTO-UHFFFAOYSA-N 0.000 claims description 70
- XLXWKULPMYZQSQ-UHFFFAOYSA-N Salvianolic acid E Natural products Cc1ccc(CC(OC(=O)C(=Cc2ccc(O)c(O)c2)c3c(O)c(O)ccc3C=CC(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)C(=O)O)cc1O XLXWKULPMYZQSQ-UHFFFAOYSA-N 0.000 claims description 70
- AMPDZVASNOBSQZ-SNVBAGLBSA-N Salvianolic acid G Natural products O=C(O)[C@H]1C(=O)C=2c3c(c(O)ccc3C1)Oc1c(O)c(O)ccc1C=2 AMPDZVASNOBSQZ-SNVBAGLBSA-N 0.000 claims description 70
- QKKVSQZGFSNHSR-UHFFFAOYSA-N Salvianolic acid I Natural products OC(=O)C(Cc1ccc(O)cc1O)OC(=O)C=Cc2ccc(OC(=Cc3ccc(O)c(O)c3)C(=O)O)c(O)c2 QKKVSQZGFSNHSR-UHFFFAOYSA-N 0.000 claims description 70
- KPKHMGUZUPELJC-UHFFFAOYSA-N Salvianolic acid J Natural products C=1C=C2OC(C=3C=C(O)C(O)=CC=3)C(C(O)=O)OC2=CC=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 KPKHMGUZUPELJC-UHFFFAOYSA-N 0.000 claims description 70
- AZOCLKLJIKZOLF-UHFFFAOYSA-N Salvianolic acid K Natural products C=1C=C(O)C(O)=CC=1C(O)C(C(O)=O)OC(C(=C1)O)=CC=C1C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 AZOCLKLJIKZOLF-UHFFFAOYSA-N 0.000 claims description 70
- 235000004883 caffeic acid Nutrition 0.000 claims description 70
- 229940074360 caffeic acid Drugs 0.000 claims description 70
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 70
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 70
- 235000001785 ferulic acid Nutrition 0.000 claims description 70
- 229940114124 ferulic acid Drugs 0.000 claims description 70
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 70
- MZSGWZGPESCJAN-JKXXRSRDSA-N melitric acid a Chemical compound C=1C=C(O\C(=C/C=2C=C(O)C(O)=CC=2)C(O)=O)C(O)=CC=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 MZSGWZGPESCJAN-JKXXRSRDSA-N 0.000 claims description 70
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 70
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 70
- 239000009574 salvianolic acid Y Substances 0.000 claims description 70
- KFCMFABBVSIHTB-ZZXKWVIFSA-N salvianolic acid g Chemical compound OC(=O)CC1=C(O)C(O)=CC=C1\C=C\C(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 KFCMFABBVSIHTB-ZZXKWVIFSA-N 0.000 claims description 70
- PULWRMOKQNWQBD-LZSLGQGWSA-N (e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1\C=C\C1=CC=C(O)C(O)=C1 PULWRMOKQNWQBD-LZSLGQGWSA-N 0.000 claims description 69
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 claims description 69
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 claims description 69
- PULWRMOKQNWQBD-UHFFFAOYSA-N salvianolic acid F Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1C=CC1=CC=C(O)C(O)=C1 PULWRMOKQNWQBD-UHFFFAOYSA-N 0.000 claims description 69
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 claims description 68
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 claims description 68
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 68
- PHJUPBDWRVMJQA-UHFFFAOYSA-N salvinal Natural products C1=C(O)C(OC)=CC(C2=C(C3=CC(CCCO)=CC(OC)=C3O2)C=O)=C1 PHJUPBDWRVMJQA-UHFFFAOYSA-N 0.000 claims description 68
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 claims description 66
- QIVXKAIEVIJKLD-UHFFFAOYSA-N Pseudoginsenoside RT3 Chemical compound C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)CO3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O QIVXKAIEVIJKLD-UHFFFAOYSA-N 0.000 claims description 66
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 64
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 claims description 64
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 claims description 63
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 61
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 61
- DMWNOMDRYALDDY-PRWHGNRFSA-N (2R,3R,4R,5R,6R)-2-[(2R,3S,4R,5R)-4,5-dihydroxy-2-[[(3S,5R,8R,9S,10S,12S,13R,14S,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-[[(2S,3S,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@@H]3[C@](C)([C@@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@@H]2[C@@H](O[C@@H]4[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O4)[C@H](O)[C@H](O)CO2)CC[C@@]31C)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](CO[C@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)O1 DMWNOMDRYALDDY-PRWHGNRFSA-N 0.000 claims description 60
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 58
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 58
- LLPWNQMSUYAGQI-QBQUQATFSA-N Ginsenoside R1 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LLPWNQMSUYAGQI-QBQUQATFSA-N 0.000 claims description 43
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 42
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 42
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 claims description 41
- KEQXHOWXGVHEHV-GGEOJOSYSA-N Notoginsenoside Q Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@@H]2[C@H](O[C@H]4[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)CO5)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)CO2)O1 KEQXHOWXGVHEHV-GGEOJOSYSA-N 0.000 claims description 38
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 claims description 33
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 claims description 33
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims description 33
- CKUVNOCSBYYHIS-SUEBGMEDSA-N (2r,3r,4s,5s,6r)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-SUEBGMEDSA-N 0.000 claims description 33
- CCDRPBGPIXPGRW-JNKODXNQSA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CCDRPBGPIXPGRW-JNKODXNQSA-N 0.000 claims description 33
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 claims description 33
- DLNAGMLXUYEHQS-UHFFFAOYSA-N 3-O-beta-D-glucopyranosylserjanic acid Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O DLNAGMLXUYEHQS-UHFFFAOYSA-N 0.000 claims description 33
- BGHNZAWRRWLKPO-UHFFFAOYSA-N Ginsenoside F1 Natural products CC(=C)CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C BGHNZAWRRWLKPO-UHFFFAOYSA-N 0.000 claims description 33
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 claims description 33
- RGDJCYRXKJVXKD-UHFFFAOYSA-N Saponin 3 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(C)C5CCC34C)C2C1)C(=O)O RGDJCYRXKJVXKD-UHFFFAOYSA-N 0.000 claims description 33
- PALNVYHUKHRDOP-UHFFFAOYSA-N UNPD162310 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O PALNVYHUKHRDOP-UHFFFAOYSA-N 0.000 claims description 33
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 claims description 33
- XNGXWSFSJIQMNC-FIYORUNESA-N ginsenoside F1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@H](O)[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XNGXWSFSJIQMNC-FIYORUNESA-N 0.000 claims description 33
- QUNSGRLNZDSQJC-ZSTWOJQOSA-N ginsenoside Ra3 Natural products O([C@](CC/C=C(\C)/C)(C)[C@H]1[C@@H]2[C@@H](O)C[C@H]3[C@@](C)([C@@]2(C)CC1)CC[C@@H]1C(C)(C)[C@H](O[C@@H]2[C@@H](O[C@@H]4[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O4)[C@H](O)[C@H](O)[C@@H](CO)O2)CC[C@@]31C)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@H](O[C@H]3[C@@H](O)[C@@H](O)[C@@H](O)CO3)[C@@H](O)[C@H](CO)O2)O1 QUNSGRLNZDSQJC-ZSTWOJQOSA-N 0.000 claims description 33
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 claims description 33
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 claims description 33
- QUNSGRLNZDSQJC-UHFFFAOYSA-N ginsenoside ra3 Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC(C1O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O QUNSGRLNZDSQJC-UHFFFAOYSA-N 0.000 claims description 33
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 claims description 33
- OSXWNRAKZUNVDR-QHEGXUBCSA-N 3-[[(2R,3S,4S,5R,6S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid Chemical compound CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C OSXWNRAKZUNVDR-QHEGXUBCSA-N 0.000 claims description 32
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 32
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 32
- OSXWNRAKZUNVDR-UHFFFAOYSA-N malonyl ginsenoside Rd Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(COC(=O)CC(O)=O)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O OSXWNRAKZUNVDR-UHFFFAOYSA-N 0.000 claims description 32
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 32
- 229930182490 saponin Natural products 0.000 claims description 32
- 150000007949 saponins Chemical class 0.000 claims description 32
- XYDGLABNHGXTRN-YLBPWTLXSA-N Notoginsenoside N Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 XYDGLABNHGXTRN-YLBPWTLXSA-N 0.000 claims description 31
- XYDGLABNHGXTRN-UHFFFAOYSA-N Notoginsenoside N Chemical compound C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(OC4C(C(O)C(O)C(CO)O4)O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O XYDGLABNHGXTRN-UHFFFAOYSA-N 0.000 claims description 31
- YQKCHRBAJSATCG-UHFFFAOYSA-N UNPD30744 Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC(C)(CCC=C(C)C)C2C3C(C4(CCC5C(C)(C)C(OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC3O)C)(C)CC2)O1 YQKCHRBAJSATCG-UHFFFAOYSA-N 0.000 claims description 31
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 claims description 31
- NODILNFGTFIURN-USYOXQFSSA-N ginsenoside Rb3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-USYOXQFSSA-N 0.000 claims description 31
- UVBLDLGZDSGCSN-UHFFFAOYSA-N ginsenoside-Rb3 Natural products C1=CC2C3(C)CCC(O)C(C)(C)C3CCC2(C)C2(C)CCC34CCC(C)C(C)C4C21OC3=O UVBLDLGZDSGCSN-UHFFFAOYSA-N 0.000 claims description 31
- SXNNDEIXKBANEP-UHFFFAOYSA-N notoginsenoside m Chemical compound C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(CO)O4)O)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SXNNDEIXKBANEP-UHFFFAOYSA-N 0.000 claims description 31
- SXNNDEIXKBANEP-YOASHVPUSA-N notoginsenoside-M Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SXNNDEIXKBANEP-YOASHVPUSA-N 0.000 claims description 31
- XEEFSHTUESCNEP-ICNXTIMXSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(2s)-2-[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-6-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12, Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O XEEFSHTUESCNEP-ICNXTIMXSA-N 0.000 claims description 30
- HERICYNRBVMDFO-WVYXDZFESA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(2s)-2-[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-3-[(2r,3r,4s,5s,6r)-3-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)CO5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HERICYNRBVMDFO-WVYXDZFESA-N 0.000 claims description 30
- RRDUCLRMPBYJEE-SJYBZOGZSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6, Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RRDUCLRMPBYJEE-SJYBZOGZSA-N 0.000 claims description 30
- ZTQSADJAYQOCDD-HUGMCNGHSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZTQSADJAYQOCDD-HUGMCNGHSA-N 0.000 claims description 30
- ZTQSADJAYQOCDD-XTHRNRJFSA-N Gypenoside IX Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@H](O)[C@H](O)CO2)O1 ZTQSADJAYQOCDD-XTHRNRJFSA-N 0.000 claims description 30
- UIFSQNKEIFIEJO-NTGAWNEPSA-N Notoginsenoside D Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)CO5)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@H](O)[C@H](O)CO3)O2)O1 UIFSQNKEIFIEJO-NTGAWNEPSA-N 0.000 claims description 30
- MYBAONSAUGZRAX-UBQYYSLZSA-N Notoginsenoside Fe Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O MYBAONSAUGZRAX-UBQYYSLZSA-N 0.000 claims description 30
- BHDLXHMEKRLJOV-UHFFFAOYSA-N Notoginsenoside K Natural products CC(C)(OO)C=CCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C BHDLXHMEKRLJOV-UHFFFAOYSA-N 0.000 claims description 30
- IWDYQBDCEDNTDP-AOSWIFJRSA-N Notoginsenoside R4 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@@H](O)[C@@H](O)CO3)O2)O1 IWDYQBDCEDNTDP-AOSWIFJRSA-N 0.000 claims description 30
- LLXVPTXOKTYXHU-HUGMCNGHSA-N O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O LLXVPTXOKTYXHU-HUGMCNGHSA-N 0.000 claims description 30
- RLDVZILFNVRJTL-IWFVLDDISA-N ginsenoside Rd Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLDVZILFNVRJTL-IWFVLDDISA-N 0.000 claims description 30
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 claims description 30
- PWVJRANWWJJIOF-QVAFKJSISA-N notoginsenoside Fa Natural products CC(=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]3CC[C@]4(C)[C@@H]3[C@H](O)C[C@@H]5[C@@]6(C)CC[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O[C@H]9[C@H](O)OC[C@@H](O)[C@@H]9O)C(C)(C)[C@@H]6CC[C@@]45C)C PWVJRANWWJJIOF-QVAFKJSISA-N 0.000 claims description 30
- UIFSQNKEIFIEJO-UHFFFAOYSA-N notoginsenoside d Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)CO4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O UIFSQNKEIFIEJO-UHFFFAOYSA-N 0.000 claims description 30
- LDCGQTUTAWJKFH-VKXLEPQWSA-N notoginsenoside-Fe Natural products O([C@](C/C=C/C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)O1 LDCGQTUTAWJKFH-VKXLEPQWSA-N 0.000 claims description 30
- -1 Sal B) Chemical compound 0.000 claims description 22
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims description 4
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims description 4
- 229930183118 Tanshinone Natural products 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 229930195208 isotanshinone Natural products 0.000 claims description 4
- OUICDHFBMJCDTL-GHRIWEEISA-N Notoginsenoside T1 Chemical compound C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(/C)=C/C(O)C1OC1(C)C OUICDHFBMJCDTL-GHRIWEEISA-N 0.000 claims description 3
- 230000036770 blood supply Effects 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- OUICDHFBMJCDTL-UHFFFAOYSA-N notoginsenoside T1 Natural products CC(=C/C(O)C1OC1(C)C)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(CO)C(O)C(O)C6O OUICDHFBMJCDTL-UHFFFAOYSA-N 0.000 claims description 3
- AVGRZVZQTALJJF-VURDRKPISA-N (2r)-3-(3,4-dihydroxyphenyl)-2-[(e)-3-(2,3,10-trihydroxybenzo[b][1]benzoxepin-7-yl)prop-2-enoyl]oxypropanoic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=CC3=CC(O)=C(O)C=C3OC=2C(O)=CC=1)C1=CC=C(O)C(O)=C1 AVGRZVZQTALJJF-VURDRKPISA-N 0.000 claims description 2
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 claims description 2
- GYQGALAEKFCZNA-UHFFFAOYSA-N C(C=CC1=CC(O)=C(OC)C=C1)(=O)O.C(C=CC1=CC(O)=C(OC)C=C1)(=O)O Chemical compound C(C=CC1=CC(O)=C(OC)C=C1)(=O)O.C(C=CC1=CC(O)=C(OC)C=C1)(=O)O GYQGALAEKFCZNA-UHFFFAOYSA-N 0.000 claims description 2
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 claims description 2
- AVGRZVZQTALJJF-UHFFFAOYSA-N Isosalvianolic acid C Natural products C=1C=C(O)C=2OC3=CC(O)=C(O)C=C3C=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 AVGRZVZQTALJJF-UHFFFAOYSA-N 0.000 claims description 2
- 229930194268 Salvianic acid Natural products 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 229930187479 gypenoside Natural products 0.000 claims description 2
- LLPWNQMSUYAGQI-UHFFFAOYSA-N notoginsenoside r1 Chemical compound C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)CO3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O LLPWNQMSUYAGQI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000007654 ischemic lesion Effects 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- YPUHYSBFIMWSEC-OEHDJSDTSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(2s)-2-[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phen Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YPUHYSBFIMWSEC-OEHDJSDTSA-N 0.000 description 116
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 88
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 66
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 66
- FNIRVWPHRMMRQI-PGOMJGFXSA-N Notoginsenoside R2 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O FNIRVWPHRMMRQI-PGOMJGFXSA-N 0.000 description 58
- YPUHYSBFIMWSEC-UHFFFAOYSA-N notoginsenoside-R3 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O YPUHYSBFIMWSEC-UHFFFAOYSA-N 0.000 description 58
- MYCOIXOUZMKBTK-FPCJEFPRSA-N (2s,3r,4s,5s,6r)-2-[(2s)-2-[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-3-[(2r,3r,4s,5s,6r)-3-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-12-hydroxy-4,4,8 Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)CO5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O MYCOIXOUZMKBTK-FPCJEFPRSA-N 0.000 description 56
- FPMOROOPDIFSMA-UHFFFAOYSA-N 2-[[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[2-[3-[3-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxyoxane-3,4,5-triol Chemical compound CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8OC9OCC(O)C(O)C9O)C(C)(C)C6CCC45C)C FPMOROOPDIFSMA-UHFFFAOYSA-N 0.000 description 56
- RWXIFXNRCLMQCD-CZIWJLDFSA-N (20R)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-CZIWJLDFSA-N 0.000 description 29
- XIRZPICFRDZXPF-GCIIHGAUSA-N 20(R)-Ginsenoside Rg3 Natural products CC(=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]6O)C(C)(C)[C@@H]4[C@@H](O)C[C@@]23C)C XIRZPICFRDZXPF-GCIIHGAUSA-N 0.000 description 29
- ZDQCRQVGMKIBPN-ONEGZZNKSA-N 4-[5-[(e)-3-hydroxyprop-1-enyl]-7-methoxy-1-benzofuran-2-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2OC3=C(OC)C=C(\C=C\CO)C=C3C=2)=C1 ZDQCRQVGMKIBPN-ONEGZZNKSA-N 0.000 description 29
- ZDQCRQVGMKIBPN-UHFFFAOYSA-N Ailanthoidol Natural products C1=C(O)C(OC)=CC(C=2OC3=C(OC)C=C(C=CCO)C=C3C=2)=C1 ZDQCRQVGMKIBPN-UHFFFAOYSA-N 0.000 description 29
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 29
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 29
- DGBYYDCXKLJFHV-UHFFFAOYSA-N chikusetsusaponin L5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC(C(C1O)O)OCC1OC1OCC(O)C(O)C1O DGBYYDCXKLJFHV-UHFFFAOYSA-N 0.000 description 29
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 29
- VAXXNBLRJUUBPR-UHFFFAOYSA-N ginsenoside F3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(CC23C)OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C VAXXNBLRJUUBPR-UHFFFAOYSA-N 0.000 description 29
- CJFGBCWGOQRURQ-JFJIKBJRSA-N ginsenoside Mc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O CJFGBCWGOQRURQ-JFJIKBJRSA-N 0.000 description 29
- CJFGBCWGOQRURQ-UHFFFAOYSA-N ginsenoside Mc Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CJFGBCWGOQRURQ-UHFFFAOYSA-N 0.000 description 29
- FUNRTBXEVGIOFB-UHFFFAOYSA-N notoginsenoside FP1 Natural products CC(=CCCC(C)(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(O)C(C)(C)C6C(CC45C)OC7OC(CO)C(O)C(O)C7O)C FUNRTBXEVGIOFB-UHFFFAOYSA-N 0.000 description 29
- XPUXIFVUABAZAP-UHFFFAOYSA-N notoginsenoside T3 Natural products CCOC(C)(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(CC23C)OC5OC(CO)C(O)C(O)C5O XPUXIFVUABAZAP-UHFFFAOYSA-N 0.000 description 29
- FNIRVWPHRMMRQI-UHFFFAOYSA-N notoginsenoside-R2 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1OC1OCC(O)C(O)C1O FNIRVWPHRMMRQI-UHFFFAOYSA-N 0.000 description 29
- 229930184988 yesanchinoside Natural products 0.000 description 29
- YDCUKUFFVMOSKZ-UHFFFAOYSA-N yesanchinoside D Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(COC(C)=O)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YDCUKUFFVMOSKZ-UHFFFAOYSA-N 0.000 description 29
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 28
- HMPXCABYJUUDEV-ZRDIBKRKSA-N Koryoginsenoside R1 Chemical compound OC1C(O)C(O)C(COC(=O)/C=C/C)OC1OC1C2C(C)(C)C(O)CCC2(C)C(CC(O)C2C3(CCC2C(C)(CCC=C(C)C)OC2C(C(O)C(O)C(CO)O2)O)C)C3(C)C1 HMPXCABYJUUDEV-ZRDIBKRKSA-N 0.000 description 28
- XBGLCVZQMWKHFC-UBJQIMRZSA-N Notoginsenoside Fc Natural products O([C@@](CC/C=C(\C)/C)(C)[C@H]1[C@@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@@H]1C(C)(C)[C@@H](O[C@@H]2[C@H](O[C@H]4[C@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O)CO5)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)[C@@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)O1 XBGLCVZQMWKHFC-UBJQIMRZSA-N 0.000 description 28
- NTAJLZDIWQCQKN-KXLUHDCESA-N Notoginsenoside O Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@H](O)CO3)[C@@H](O)CO2)O1 NTAJLZDIWQCQKN-KXLUHDCESA-N 0.000 description 28
- FAMUWZNCFCXABA-YZMVNYHOSA-N Notoginsenoside P Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)CO2)O1 FAMUWZNCFCXABA-YZMVNYHOSA-N 0.000 description 28
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 28
- 239000008103 glucose Substances 0.000 description 28
- ZRBFCAALKKNCJG-SJYBZOGZSA-N gypenoside XVII Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZRBFCAALKKNCJG-SJYBZOGZSA-N 0.000 description 28
- HMPXCABYJUUDEV-UHFFFAOYSA-N koryoginsenoside-R1 Natural products CC=CC(=O)OCC1OC(OC2CC3(C)C(CC(O)C4C(CCC34C)C(C)(CCC=C(C)C)OC5OC(CO)C(O)C(O)C5O)C6(C)CCC(O)C(C)(C)C26)C(O)C(O)C1O HMPXCABYJUUDEV-UHFFFAOYSA-N 0.000 description 28
- XBGLCVZQMWKHFC-UHFFFAOYSA-N notoginsenoside fc Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)CO4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O XBGLCVZQMWKHFC-UHFFFAOYSA-N 0.000 description 28
- AZIGQTILUNTIQH-VJKRGORSSA-N notoginsenoside-S Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)CO5)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@@H](O)[C@@H](O)[C@@H](O)CO3)O2)O1 AZIGQTILUNTIQH-VJKRGORSSA-N 0.000 description 28
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 8
- 239000012264 purified product Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition and application thereof. Specifically, the pharmaceutical composition comprises: salvianolic acid as a first active ingredient; and ginsenoside as a second active ingredient. The pharmaceutical composition has more excellent curative effect on preventing and/or treating ischemic diseases and ischemia-reperfusion tissue organ injury, and can be used for treating ischemia and/or ischemia-reperfusion injury of different tissue organs.
Description
Technical Field
The invention relates to the field of medicines, in particular to a pharmaceutical composition and application thereof in preventing and/or treating ischemic diseases and/or ischemia-reperfusion injuries and other diseases.
Background
The blood vessels are responsible for supplying blood to tissue organs of the whole body, once the blood vessels are blocked, the tissue organs cause diseases due to insufficient blood supply, and particularly the tissue organs such as the heart, the brain and the like with high requirements on blood oxygen supply; and with the establishment, popularization and application of methods such as microcirculation dredging during shock, coronary spasm relieving, artery bypass surgery, thrombolytic therapy, percutaneous transluminal coronary angioplasty, cardiac surgery extracorporeal circulation, mechanical thrombus removal, cardio-pulmonary-cerebral resuscitation, limb replantation, organ transplantation and the like, blood supply (namely reperfusion) can be restored after a plurality of tissues and organs are ischemic. However, such reperfusion after ischemia may not only fail to restore the function of tissues and organs, but also aggravate the dysfunction and structural damage of tissues and organs. The phenomenon that tissue damage is rather increased after blood flow is restored on the basis of ischemia and even irreversible damage occurs is called ischemia-reperfusion injury.
Although some pharmaceutical compositions comprising the compounds salvianolic acid and ginsenoside have been disclosed to date, they have therapeutic effects on cardiac ischemia-reperfusion injury. However, the research on the compatibility of the two drugs is not sufficient, and further research on the compatibility of the two drugs needs to be carried out to provide a pharmaceutical composition with better curative effect on ischemia-reperfusion injury of different tissues and organs.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for preventing and/or treating diseases such as tissue and organ ischemia, ischemia reperfusion injury and the like.
1. A pharmaceutical composition, comprising:
(a) a first active ingredient selected from the group consisting of: salvianolic acid, a stereoisomer, a crystalline form, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, an extract containing salvianolic acid, or a combination thereof;
(b) a second active ingredient selected from the group consisting of: ginsenoside, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, a ginsenoside-containing extract, or a combination thereof; and
(c) a pharmaceutically acceptable carrier;
and the weight ratio of the first active ingredient to the second active ingredient is 1-100:100-1, wherein the weight ratio is calculated by salvianolic acid and ginsenoside compound.
In another preferred embodiment, the weight ratio of the first active ingredient to the second active ingredient is 1-50:50-1, preferably 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5: (2-3.0).
In another preferred embodiment, the salvianolic acid is selected from the group consisting of: salvianolic acid B (Salvianolic acid B, Sal B), Salvianolic acid A (Salvianolic acid A, Sal A), Salvianolic acid C (Salvianolic acid C, Sal C), iso-Sal C (Isosalvianolic acid C), Salvianolic acid D (Salvianolic acid D, Sal D), Salvianolic acid E (Salvianolic acid E, Sal E), Salvianolic acid F (Salvianolic acid F, Sal F), Salvianolic acid G (Salvianolic acid G, Sal G), Salvianolic acid H (Salvianolic acid H, Sal H), Salvianolic acid I (Salvianolic acid I, Sal I), Salvianolic acid J (Salvianolic acid J, Sal J), Salvianolic acid K (Salvianolic acid K, K), Salvianolic acid L (Salvianolic acid L, Sal L), Salvianolic acid L (Salvianolic acid M), Sal N (Sal M, Sal D E, Sal E, Sal E, Sal E, Sal E, Sal E, Sal E B, Sal E, Sal E B, Sal E B, Sal E, u), Salvianolic Acid Y (Salvianolic Acid Y, Sal Y), Caffeic Acid (Caffeic Acid), Danshensu (Danshensu), Protocatechuic Acid (protocatholic Acid), protocatechualdehyde (protocatholic aldehyde), Ferulic Acid (Ferulic Acid), Isoferulic Acid (Isoferulic Acid), Salvinal Acid, alanthodol, Rosmarinic Acid (Rosmarinic Acid), Lithospermic Acid (Lithospermic Acid), salvianic Acid (Lithospermic Acid), salvianoside (salvianoside), catechol (cathecol), dimethyllithospermidine b (dimethyllithotanshinone I), tanshinone I (tanshinone I), dihydrotanshinone I, salviandiol-a (salviandiol iia-a), tanshinone (tanshinone), cryptotanshinone (cryptotanshinone), neotanshinone (neotanshinone a), isotanshinone (isotanshinone a), or a combination thereof.
In another preferred embodiment, the ginsenoside is selected from the group consisting of: ginsenoside Re (Ginsenoside Re), Ginsenoside Rg1(Ginsenoside Rg1), Ginsenoside Rg2(Ginsenoside Rg2), Ginsenoside Rh1(Ginsenoside Rh1), Ginsenoside F1(Ginsenoside F1), Notoginsenoside R1 (Notogenoside R1), Notoginsenoside R1 (Notogenoside R1), Notoginsenoside M (Notogenoside M), Notoginsenoside N Notogenoside N FP N (Notogenoside N), Notoginsenoside Rt (Notogenoside Rt), Notoginsenoside T1 (Notogenoside T1), Notoginsenoside T1 (Notogenoside 1), Notoginsenoside Re (Notoginsenoside Wolginsenoside 1), Notoginsenoside Rg (Notoginsenoside Rg), Notoginsenoside T1-sanchinoside 1(Notoginsenoside Wo-1), Notoginsenoside R1(Notoginsenoside R1), Notoginsenoside R1-D-1), Notoginsenoside 1(Notoginsenoside 1), Notoginsenoside R1(Notoginsenoside R1), Ginsenoside R1(Notoginsenoside R1) and D, Pseudoginsenoside RT3(Pseudoginsenoside RT3), saponin 10(saponin 10), saponin 1(saponin 1), saponin 2(saponin 2), saponin 3(saponin 3), Ginsenoside Ra3(Ginsenoside Ra3), Ginsenoside Rb1(Ginsenoside Rb1), Ginsenoside Rb2(Ginsenoside Rb2), Ginsenoside Rb3(Ginsenoside Rb 8), Ginsenoside Rc (Ginsenoside Rc), Ginsenoside Rd, Ginsenoside Rg3(Ginsenoside Rg3), Ginsenoside Rb1 (cinnamyl-Ginsenoside Rb1), Malonyl Ginsenoside Rd (Malonyl-Ginsenoside Rd), Ginsenoside Rd 3 (6' -O-acetyl-Rg 4642), Ginsenoside Rd 584620 (Ginsenoside CK 4620) -Ginsenoside Rd 4620 (Ginsenoside Rd), Ginsenoside Rg 584648 (Ginsenoside Rg 4620), Ginsenoside Rg 4620 (Ginsenoside Rd) -Ginsenoside Rg 4620 (Ginsenoside Rd), Ginsenoside Rg3(Ginsenoside Rg 465) and Ginsenoside Rg3(Ginsenoside Rg 4620) and Ginsenoside Rd, 20(R) -Ginsenoside Rh2(20(R) -Ginsenoside Rh2), 20(S) -Ginsenoside Rh2(20(S) -Ginsenoside Rh2), Notoginsenoside R4 (Notogenoside R4), Notoginsenoside K (Notogenoside K), gypenoside (Gypensoside XVII), gypenoside IX (Gypensoside IX), gypenoside XV (Gypensoside XV), gypenoside VIII (Gypensoside VIII), Notoginsenoside Fa (Notogenoside Fa), Notoginsenoside (Fc) Notogenoside Fc, Notoginsenoside Fe (Notogenoside Fe), Notoginsenoside D (Notogenoside D), Notoginsenoside L (Notogenide L), Notoginsenoside L (Notogenoside L), Notoginsenoside (Notogenoside Fnoside FP), Notoginsenoside (Notogenoside F2), Notoginsenoside Q (Notogenoside F) and Notoginsenoside Q (Notogenoside F) (Notogenoside FP), Notoginsenoside Q (Notogenoside Q) (Notogenoside F) (Notogenoside FP), Notoginsenoside Q (Notogenoside F) (Notogenoside FP), Notoginsenoside Q) (Notogenoside F) (I), Notoginsenoside F) (Notogenoside F) (Notogenin F) (Notogenide F) (I), notoginsen(Notogenoside F) (Notogenide F) (for the same, F) (for the same or the same) and F) (for the same of Notogenide F) (for the same of Notogenin) of Notogenin F) (for the same of Notogenin F) (for the same of Notogenin) of Notogenin the same of Notogenin F) (for the same of Notogenin the same of Not, Notoginsenoside ST-4 (Notogenoside ST-4), Notoginsenoside FZ (Notogenoside FZ), Notoginsenoside Fh1 (Notogenoside Fh1), or a combination thereof.
In another preferred embodiment, the first active ingredient comprises a purified product of salvianolic acid or a pharmaceutically acceptable salt thereof.
In another preferred embodiment, the purity of the purified product is greater than or equal to 90%, preferably greater than or equal to 95%, more preferably greater than or equal to 98% or 99%, based on the total weight of the purified product, based on the salvianolic acid.
In another preferred embodiment, the content of salvianolic acid C1 in the extract is greater than or equal to 70%, preferably greater than or equal to 80%, more preferably greater than or equal to 90% or greater than or equal to 95%, based on the dry weight of the extract.
In another preferred embodiment, the first active ingredient comprises a purified product of ginsenoside or a pharmaceutically acceptable salt thereof.
In another preferred embodiment, the purity of the purified product is greater than or equal to 90%, preferably greater than or equal to 95%, more preferably greater than or equal to 98% or 99%, based on the total weight of the purified product.
In another preferred embodiment, the content of ginsenoside C2 in the extract is greater than or equal to 70%, preferably greater than or equal to 80%, more preferably greater than or equal to 90% or greater than or equal to 95%, based on the dry weight of the extract.
In another preferred embodiment, the dosage form of the pharmaceutical composition is selected from the group consisting of: liquid formulations (e.g., solutions, emulsions, suspensions), solid formulations (e.g., lyophilized formulations), gaseous formulations, semisolid formulations. .
In another preferred embodiment, the dosage form is selected from the group consisting of: injection (such as injection or powder injection), oral preparation (such as capsule, tablet, pill, powder, granule, syrup, oral liquid or tincture), sublingual buccal preparation, respiratory tract administration preparation, skin administration preparation, mucosa administration preparation, preferably, the dosage form is injection.
In another preferred embodiment, the pharmaceutical composition comprises a combination of active ingredients selected from the group consisting of:
salvianolic acid B and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rg1 malonate preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3) salvianolic acid B and saponin 1, preferably in a weight ratio;
Salvianolic acid B and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
Salvianolic acid B and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rb1 malonate preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid B to the notoginsenoside Fe is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside P preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid B and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid B and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid A to the notoginsenoside N is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid A and the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the salvianolic acid A to the malonic acid ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and saponin 10 preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianolic acid A to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid A to the saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and saponin 3 preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rb malonate 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and 20(S) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and 20(R) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1 salvianolic acid A and gypenoside VIII, preferably 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid A and notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside S preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid A and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid A and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and ginsenoside Rg1 malonate preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianolic acid C to saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid C to saponin 3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid C to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rb1 malonate preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and 6' -O-acetyl ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside K, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside Ftl preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid C and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid C and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
preferably the weight ratio of the iso-Sal C to the ginsenoside Rg2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside M is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Preferably the weight ratio of the iso-Sal C to the notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
preferably the weight ratio of the iso-Sal C to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside RW1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the 20-glucose ginsenoside Rf is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the malonic acid ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the chikusetsusaponin L5 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and koryaginsoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the iso-Sal C to the saponin 10 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the different Sal C and saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the saponin 2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the iso-Sal C to saponin 3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Preferably the weight ratio of the iso-Sal C to the ginsenoside Rg3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and malonate ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the malonyl ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-SalC and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-SalC and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside K is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
preferably the weight ratio of the iso-Sal C to the gypenoside XVII is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
preferably the weight ratio of the iso-Sal C to the gypenoside IX is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Preferably the weight ratio of the iso-Sal C to the gypenoside XV is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the gypenoside VIII is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside L is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
preferably the weight ratio of the iso-Sal C to the notoginsenoside L is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
preferably the weight ratio of the iso-Sal C to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside P is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside T is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside FP2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside Ftl is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside ST-4 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the notoginsenoside FZ is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-Sal C and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-Sal C to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-SalC and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid D and Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and ginsenoside Rg1 malonate preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid D to saponin 10 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid D and saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rb1 malonate, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside Fa, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid D and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid D to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid D and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid E to the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid E to the Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianolic acid E to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid E to saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the salvianolic acid E to the notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid E and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid E and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid F to the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the salvianolic acid F to the malonic acid ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianolic acid F to saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rb malonate 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and 20(S) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside P preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid F and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid F and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the salvianolic acid G to the malonic acid ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of salvianolic acid G to saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid G to saponin 3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid G to the ginsenoside Rc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Rb1 malonate preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and 20(S) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and 20(R) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the salvianolic acid G to the notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside L preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid G to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid G to the notoginsenoside Ftl is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid G and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid G and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid G to the ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid H and notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid H to the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of salvianolic acid H and saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid H and saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid H to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid H and gypenoside XV is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside Fa, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid H and notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid H and the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid H and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid H and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid I and notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid I and the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid I to the Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferred weight ratio of the salvianolic acid I to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid I and saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid I and ginsenoside Rc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid I to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside CK preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside Fa preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid I and notoginsenoside Fe is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside D preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside L preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid I and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid I to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid I and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid J and the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid J to the saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid J to the saponin 3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and 20(S) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside Fa preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid J and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid J and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the ginsenoside Rg2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1 salvianolic acid K and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside R2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside R3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside R6 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid K to notoginsenoside N is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianolic acid K to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid K to the saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid K to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside R4 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid K to notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside P preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid K to the notoginsenoside Q is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid K and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid K to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid K and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid L and notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid L to saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid L and notoginsenoside Fe is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid L and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid L and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid M to the ginsenoside Rg2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1 salvianolic acid M and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid M and notoginsenoside R2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid M and notoginsenoside R6 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid M and notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid M and the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Rb malonate 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid M and gypenoside XV is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid M to the notoginsenoside Fc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid M to notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside D preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid M and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid M and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid M to the ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rh1 preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid N and notoginsenoside R1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid N and notoginsenoside R2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid N and notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid N to the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid N to notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid N and notoginsenoside Fh1, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid N to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid N and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid T to saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid T to saponin 3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid T to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid T and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid T and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid U and the ginsenoside Rg2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid U to the ginsenoside Rh1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid U and notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid U and the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid U and Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Rb malonate 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianolic acid U to the malonyl ginsenoside Rd is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and 20(S) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and 20(R) -ginsenoside Rg3, preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid U and notoginsenoside R4 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid U to the gypenoside IX is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferred weight ratio of the salvianolic acid U and notoginsenoside Fa is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid U and notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid U and notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid U and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid U and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid U and the ginsenoside Re is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid U and the ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid Y to the notoginsenoside R3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid Y and notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid Y to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of salvianolic acid Y to saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid Y to saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of salvianolic acid Y to ginsenoside Rc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianolic acid Y to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid Y to the ginsenoside Rg3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid Y to the malonic acid ginsenoside Rb1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the salvianolic acid Y to the 6' -O-acetyl ginsenoside Rg3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1: 10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianolic acid Y to the ginsenoside Mc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferred weight ratio of the salvianolic acid Y to the notoginsenoside K is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid Y to gypenoside IX is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of salvianolic acid Y to notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of salvianolic acid Y to notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid Y and notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianolic acid Y and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of salvianolic acid Y and ginsenoside Re is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianolic acid Y and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside Rt, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and Yesanchinoside U, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and malonic acid ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and chikusetsusaponin L5, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and saponin 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and saponin 3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rb malonate 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and gypenoside IX, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and gypenoside XV, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside Fe, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside FP2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside Ftl, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Caffeic acid and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
caffeic acid and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and Yesanchinoside U, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and saponin 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and saponin 2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and saponin 3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and ginsenoside Rb malonate 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Fe preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Danshensu and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshensu and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Fa, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Fe, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside FP2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechuic acid and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechuic acid and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and malonicacid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Protocatechualdehyde and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
protocatechualdehyde and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside Rt, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside Fe, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ferulic acid and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ferulic acid and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and notoginsenoside Rt, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and Yesanchinoside U, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside Fe, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Isoferulic acid and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
isoferulic acid and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and 20-glucosyl ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Fa, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Fe preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvinal and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvinal and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside Rt, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidal and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidal and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidal and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidal and 20(S) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and 20(R) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside Fe, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidal and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidol and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Ailanthoidol and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
ailanthoidal and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Fa preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside L preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Rosmarinic acid and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
rosmarinic acid and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Rc preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and 20(S) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and 20(R) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and notoginsenoside Fa preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside D preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside L preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside P preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside S preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
lithospermic acid and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Lithospermic acid and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the danshenglycoside to the notoginsenoside R2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the danshenglycoside to the notoginsenoside R3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the danshenglycoside to the notoginsenoside R6 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the notoginsenoside M is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
danshenside and Yesanchinoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the danshenoside to the Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the danshenglycoside to the malonic acid ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and koryoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the saponin 10 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the saponin 3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and malonic acid ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the danshenglycoside to the ginsenoside CK is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the notoginsenoside K is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the notoginsenoside Fe is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A glycoside to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside FP2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside Ftl, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid A and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A to the ginsenoside Re is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid A and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and malonicacid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and 20(S) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and 20(R) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and notoginsenoside Fa, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside Fe preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
catechol and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Catechol and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside N preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and 20-glucose ginsenoside Rf, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and 20(S) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and 20(R) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside Fa preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside Fe preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dimethyl lithospermic acid B and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dimethyl lithospermic acid B and ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and Yesanchinoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and Yesanchinoside U, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and malonic acid ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside Fa, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside Fe, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone I and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone I and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside Rt, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and Yesanchinoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and Yesanchinoside U, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and malonic acid ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and koryoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and saponin 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and saponin 2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and malonic acid ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and gypenoside XV, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside Fe, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside FP2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dihydrotanshinone I and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dihydrotanshinone I and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza diol-A to the ginsenoside Rg2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the ginsenoside Rh1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza diol-A and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside R1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside R2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside R3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside R6 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the notoginsenoside M is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza diol-A to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside FP1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the notoginsenoside RW1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the malonic acid ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the chikusetsusaponin L5 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the saponin 2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza diol-A and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the ginsenoside Rc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the ginsenoside Rd is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza diol-A to the ginsenoside Rg3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza diol-A and malonate ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and ginsenoside F2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza diol-A to the ginsenoside CK is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the ginsenoside Mc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the notoginsenoside R4 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside K is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the gypenoside IX is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the gypenoside XV is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside Fa is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside Fc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside L is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside P is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside FP2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside Ftl is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the notoginsenoside ST-4 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvianediol-A to the notoginsenoside FZ is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza diol-A and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the ginsenoside Re is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianediol-A to the ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside N, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Rt, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and Yesanchinoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and malonate ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and malonate ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Fe, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside O, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Tanshinone IIA and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Re, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
tanshinone IIA and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and ginsenoside Rh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside N, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Rt, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and Yesanchinoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and Yesanchinoside U, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and malonic acid ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and chikusetsusaponin L5, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and koryoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and saponin 10, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and saponin 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and saponin 2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and saponin 3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and ginsenoside Rb1 malonate, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside CK, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and gypenoside XVII, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and gypenoside XV, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Fa, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Fe, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside O, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Cryptotanshinone and notoginsenoside FZ, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
cryptotanshinone and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoketone to the ginsenoside Rg2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Red sage neoketone and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvianic acid A neoketone to the notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoketone to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoketone to the malonic acid ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoketone to the saponin 1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside Rc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoketone to the ginsenoside Rg3 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and malonyl ginsenoside Rd, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and ginsenoside CK, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Red sage neoketone and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside K, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianic acid neoketone to the gypenoside IX is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianic acid neoketone to the notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoketone to the notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
red sage neoketone and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoketone to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvianic acid A neoketone to the notoginsenoside P is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and notoginsenoside S, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvianic acid neoketone and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvianic acid neoketone and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoketone to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoketone to the ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Rg2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and ginsenoside Rh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside F1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside R2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside R3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside M, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the dehydrodanshenxintong to the notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the dehydrodanshenxintong to the notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside T3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and notoginsenoside FP1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside RW1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside Fh7, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxinodone and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxinodone and Yesanchinoside U, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and 20-glucosyl ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and malonic acid ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and chikusetsusaponin L5, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and koryoginsenoside R1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and pseudoginsenoside RT3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydro-danshenxinone and saponin 10, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydro-danshenxinone and saponin 1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydro-danshenxinone and saponin 2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydro-danshenxinone and saponin 3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Ra3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Rb2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Rb3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Rc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydro-danshenxintong and malonic acid ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and malonyl ginsenoside Rd, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and 6' -O-acetyl ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside F2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and ginsenoside CK preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Mc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and 20(R) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and 20(S) -ginsenoside Rh2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside R4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydro-danshenxintong and gypenoside IX, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydro-danshenxintong and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of dehydrodanshenxintong to notoginsenoside Fa is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside Fc, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the dehydrodanshenxintong to the notoginsenoside Fe is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside L preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside O preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside P, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydrodanshenxintong and notoginsenoside Q, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside S preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside T, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside FP2, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the dehydrodanshenxintong to the notoginsenoside Ftl is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Dehydro-danshenxintong and notoginsenoside ST-4, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside FZ preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Re, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
dehydrodanshenxintong and ginsenoside Rg1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the ginsenoside Rg2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the ginsenoside Rh1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the ginsenoside F1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside R1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside R2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the notoginsenoside R3 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and notoginsenoside R6, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside M is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside N is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the notoginsenoside Rt is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Iso-tanshinone I and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside FP1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside Fh7 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the isotanshinone I and the Yesanchinoside D is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the iso-tanshinone I and the Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the 20-glucose ginsenoside Rf is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the isotanshinone I to the malonic acid ginsenoside Rg1 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the isotanshinone I to the chikusetsusaponin L5 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the koryoginsenoside R1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferred weight ratio of the isotanshinone I to the pseudoginsenoside RT3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the saponin 10 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the saponin 1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the saponin 2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the saponin 3 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the ginsenoside Ra3 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the ginsenoside Rb1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the ginsenoside Rb2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the ginsenoside Rb3 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the ginsenoside Rc is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the ginsenoside Rg3 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and malonic acid ginsenoside Rb1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the malonyl ginsenoside Rd is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferred weight ratio of the isotanshinone I to the 6' -O-acetyl ginsenoside Rg3 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the ginsenoside F2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the ginsenoside CK is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the ginsenoside Mc is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and 20(S) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Iso-tanshinone I and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside R4 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside K is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the iso-tanshinone I to the gypenoside XVII is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the gypenoside IX is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the isotanshinone I to the gypenoside XV is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the gypenoside VIII is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside Fc is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the notoginsenoside Fe is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside D is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside L is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside L is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the notoginsenoside O is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the notoginsenoside P is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside Q is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside S is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside T is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside FP2 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the notoginsenoside Ftl is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside ST-4 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the isotanshinone I to the notoginsenoside FZ is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
iso-tanshinone I and notoginsenoside Fh1, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the iso-tanshinone I to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the isotanshinone I to the ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Rg2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Rh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside F1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and notoginsenoside R2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside R3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside R6, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside M, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoquinone to the notoginsenoside N is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of salvia miltiorrhiza neoquinone to notoginsenoside Rt is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside T3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
red sage neoquinome and notoginsenoside FP1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside RW1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside Fh7, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and Yesanchinoside D, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the red sage neoquinone to the Yesanchinoside U is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinonoid and 20-glucose ginsenoside Rf, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and malonic acid ginsenoside Rg1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinonoid and chikusetsusaponin L5, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and koryoginsenoside R1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and pseudoginsenoside RT3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoquinone to the saponin 10 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone 1 and saponin 1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and saponin 2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and saponin 3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Ra3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Rb2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Rb3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvia miltiorrhiza neoquinone to the ginsenoside Rc is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone is preferably added to ginsenoside Rd at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and malonic acid ginsenoside Rb1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone is preferably added to malonyl ginsenoside Rd at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and 6' -O-acetyl ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the preferable weight ratio of the salvia miltiorrhiza neoquinone formazan to the ginsenoside F2 is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone is preferably added to the ginsenoside CK at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and ginsenoside Mc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and 20(S) -ginsenoside Rg3, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinome and 20(R) -ginsenoside Rg3, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
red sage neoquinome and 20(R) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinonedia and 20(S) -ginsenoside Rh2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside R4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside K, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Red sage neoquinone and gypenoside XVII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoquinone to the gypenoside IX is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and gypenoside XV, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
red sage neoquinone and gypenoside VIII, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
the weight ratio of the salvia miltiorrhiza neoquinone to the notoginsenoside Fa is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and notoginsenoside Fc, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone is preferably added to the panax notoginseng saponin Fe in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside D, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside L, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside L, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The preferable weight ratio of the salvia miltiorrhiza neoquinone to the notoginsenoside O is 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside P, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside Q, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside S, preferably at a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside T, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
Salvia miltiorrhiza neoquinone and notoginsenoside FP2, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside Ftl, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
red sage neoquinome and notoginsenoside ST-4, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone A and notoginsenoside FZ, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
salvia miltiorrhiza neoquinone and notoginsenoside Fh1, preferably in a weight ratio of 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3);
The weight ratio of the salvia miltiorrhiza neoquinone to the ginsenoside Re is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3); or
The weight ratio of the salvia miltiorrhiza neoquinone to the ginsenoside Rg1 is preferably 1-100:100-1, 1-50:50-1, 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3).
In a second aspect of the invention, there is provided a combination of active ingredients, said combination of active ingredients comprising:
(a) a first active ingredient selected from the group consisting of: salvianolic acid, a stereoisomer, a crystalline form, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, an extract containing salvianolic acid, or a combination thereof;
(b) a second active ingredient selected from the group consisting of: ginsenoside, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, a ginsenoside-containing extract, or a combination thereof;
and the weight ratio of the first active ingredient to the second active ingredient is 1-100:100-1, wherein the weight ratio is calculated by salvianolic acid and ginsenoside compound.
In another preferred embodiment, the weight ratio of the first active ingredient to the second active ingredient is 1-50:50-1, preferably 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5: (2-3.0).
In another preferred embodiment, the combination of active ingredients consists of (a) a first active ingredient and (b) a second active ingredient.
In a third aspect of the invention, there is provided a kit comprising:
a first pharmaceutical composition comprising: (a) a first active ingredient selected from the group consisting of: salvianolic acid, a stereoisomer, a crystalline form, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, an extract containing salvianolic acid, or a combination thereof; and a pharmaceutically acceptable carrier;
a second pharmaceutical composition comprising: (b) a second active ingredient selected from the group consisting of: ginsenoside, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, a ginsenoside-containing extract, or a combination thereof; and a pharmaceutically acceptable carrier;
And the first and second pharmaceutical compositions are administered in combination, wherein the weight ratio of the first and second active ingredients is 1-100:100-1, wherein the weight ratio is based on salvianolic acid and ginsenoside compounds.
In another preferred embodiment, the weight ratio of the first active ingredient to the second active ingredient is 1-50:50-1, preferably 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5 (2-3.0).
In another preferred embodiment, the first and second pharmaceutical compositions are different (or separate) pharmaceutical compounds, or are the same pharmaceutical composition.
In a fourth aspect of the invention, there is provided a pharmaceutical composition according to the first aspect of the invention, a combination of active ingredients according to the second aspect of the invention, or a use of a kit according to the third aspect of the invention, for the manufacture of a medicament or kit for (i) the prevention and/or treatment of an ischemic disease; (ii) prevention and/or treatment of ischemia reperfusion injury; (iii) inhibit lactate dehydrogenase.
In another preferred embodiment, the medicament or kit is for use in (i) the prevention and/or treatment of ischemic heart disease; (ii) prevention and/or treatment of ischemia reperfusion injury; (iii) (iii) inhibition of lactate dehydrogenase and/or (iv) prevention and/or treatment of ischemic diseases.
In another preferred embodiment, the ischemic disease is selected from the group consisting of: acute ischemia-induced tissue organ damage and/or chronic ischemia-induced tissue organ damage.
In another preferred embodiment, the ischemic disease is selected from the group consisting of: ischemic injury of tissues and organs due to primary lesions of tissues and blood vessels, and/or ischemic lesions due to secondary causes, such as blood vessel detachment due to trauma, blood vessel occlusion due to inflammation, and blood vessel compression due to tumor.
In another preferred embodiment, the ischemic disease is selected from the group consisting of: ischemic heart disease, ischemic stroke (such as acute cerebral infarction), ischemic liver injury, pulmonary embolism, ischemic kidney injury, ischemic nerve injury, or a combination thereof.
In another preferred example, the ischemic heart disease comprises: coronary heart disease, myocardial infarction, angina pectoris, myocardial fibrosis, heart failure, or a combination thereof.
In another preferred embodiment, the ischemia reperfusion injury is tissue organ injury caused by reperfusion.
In another preferred embodiment, the tissue organ is selected from the group consisting of: heart, brain, liver, spleen, lung, kidney, muscle, nerve, or combinations thereof. In another preferred embodiment, the tissue organ is selected from the group consisting of: liver, spleen, lung, kidney, brain, nerves, or combinations thereof.
In another preferred embodiment, the tissue organ is selected from the group consisting of: heart, brain, or a combination thereof.
In another preferred embodiment, the medicament or kit is further used for ameliorating pulmonary embolism induced myocardial hypertrophy. In another preferred embodiment, the medicament or kit is further for improving the diastolic function of a reperfusion-damaged heart, preferably, the diastolic function of the heart comprises the diastolic rate of the heart.
In another preferred embodiment, the medicament or kit is also used for improving the contractile function of the heart (e.g., the rate of contraction of the heart).
In another preferred embodiment, the medicament or kit is for improving reperfusion injury of the kidney, preferably comprising improving kidney architecture.
In another preferred embodiment, the tissue organ injury is a post-operative reperfusion injury, preferably the operation is selected from the group consisting of: arterial bypass, embolectomy or thrombolytic therapy, percutaneous transluminal coronary angioplasty, cardiopulmonary and/or cerebral resuscitation after cardiac arrest, reperfusion injury from amputation or organ transplantation, or other major surgery.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be repeated herein, depending on the space.
Detailed Description
The invention provides a medicine composition containing salvianolic acid and ginsenoside as active ingredient ratios through extensive and intensive research and a large number of screens and tests, and the medicine comprises the active ingredients with specific combination and/or specific ratio, and has more excellent improvement and treatment effects on ischemic diseases and ischemia-reperfusion injury of tissue organs; and surprisingly, the composition has curative effect on ischemia-reperfusion injury of organs such as heart, brain, liver, kidney and the like, and can be used for ischemia-reperfusion injury of various tissue organs. The present invention has been completed based on this finding.
Term(s) for
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, the term "about" when used in reference to a specifically recited value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
As used herein, when referring to specifically enumerated values, the ratio of "1 to 100:100 to 1" can also be expressed as (1 to 100) to (1 to 100) or "(1 to 100) to (100 to 1)".
As used herein, the term "comprising" or "includes" can be open, semi-closed, and closed. In other words, the term also includes "consisting essentially of …," or "consisting of ….
As used herein, the term "stereoisomer" is intended to include all isomeric forms (e.g., enantiomers, diastereomers, and geometric isomers (or conformational isomers)): for example, R, S configuration containing an asymmetric center, (Z), (E) isomers of double bonds, and the like. Thus, individual stereochemical isomers of the active ingredients of the present invention or mixtures of enantiomers, diastereomers or geometric isomers (or conformers) thereof are within the scope of the present invention.
The active ingredients of the present invention may be amorphous, crystalline or mixtures thereof. Prodrugs and solvates of the compounds of the invention are also contemplated. The term "prodrug" as used herein refers to a compound that undergoes chemical conversion by metabolic or chemical processes to yield a compound, salt, or solvate of the present invention when used in the treatment of a related disease. The compounds of the present invention include solvates, such as hydrates.
As used herein, "pharmaceutically acceptable salt" refers to a salt formed by a compound of the active ingredient of the present invention and an acid or a base, which is suitable for use as a medicament. Pharmaceutically acceptable salts include inorganic and organic salts. One preferred class of salts is that formed between the compounds of the active ingredients of the present invention and an acid. Suitable acids for forming the salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, etc., organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, phenylmethanesulfonic acid, benzenesulfonic acid, etc.; and acidic amino acids such as aspartic acid and glutamic acid. One preferred class of salts is that formed by reacting a compound of the active ingredient of the invention with a base. Suitable bases for salt formation include, but are not limited to: inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate and sodium phosphate, and organic bases such as ammonia, triethylamine and diethylamine. Another preferred class of salts are those formed with metal ions of the active ingredients of the present invention, including but not limited to magnesium, sodium, calcium, potassium, and the like.
As used herein, "pharmaceutically acceptable ester" refers to esters of compounds of the active ingredients of the present invention with acids or alcohols suitable for use as pharmaceuticals-a preferred ester is an ester of one or more of the hydroxyl groups of the active ingredients of the present invention with an acid, and acids suitable for forming esters include, but are not limited to: phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, phenylmethanesulfonic acid, benzenesulfonic acid, etc.; another preferred class of esters are esters of the carboxyl groups of the active ingredients of the present invention with alcohols, suitable ester-forming alcohols include, but are not limited to: C1-C6 alkyl-OH, such as methanol, ethanol, n-propanol, isopropanol, etc.
The active ingredients of the present invention may also include derivatives of compounds including: a compound formed by substitution of one or more (2, 3 or 4) H on the active compound with a group selected from the group consisting of: halogen, CN, OH, -COOH, oxo, -NH2, a monosaccharide radical (e.g. glucosyl), a disaccharide radical (e.g. diglucosyl), a halogen substituted or unsubstituted-C1-C8 alkoxy, one or two halogen substituted or unsubstituted C1-C8 alkyl substituted amino-, halogen substituted or unsubstituted C1-C8 alkyl, halogen substituted or unsubstituted C2-C8 alkenyl, halogen substituted or unsubstituted C2-C8 alkynyl, - (C ═ O) -halogen substituted or unsubstituted C1-C8 alkyl, halogen substituted or unsubstituted C3-C10 cycloalkyl, 3-10 membered heterocycloalkyl having 1-3 heteroatoms selected from the following groups N, S and O, C6-C10 aryl, or 5-10 membered heteroaryl having 1-3 heteroatoms selected from the following groups N, S and O. Such as ether linkages (substituted with alkoxy groups) which may be formed when OH groups are present in the molecule of the compound, suitable reagents for forming ethers with the active compounds of the invention include, but are not limited to: C1-C6 alkyl-OH such as methanol, ethanol, n-propanol, isopropanol, etc.; OH can also be further oxidized to aldehyde; or atoms in the molecule may optionally be oxidized (to form aldehydes, ketones or carboxylic acids), derivatives of these active compounds are included within the scope of the present invention.
In another preferred embodiment, the alkyl, alkenyl, alkynyl independently optionally comprises 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
In another preferred embodiment, the halogen includes fluorine, chlorine, bromine, iodine.
In another preferred embodiment, "cycloalkyl", "heterocycloalkyl", independently, optionally include 4, 5, 6, 7 or 8 ring atoms.
In another preferred embodiment, "aryl" includes phenyl, naphthyl, or biphenyl. "heterocycloalkyl" independently optionally includes 5, 6, 7, or 8 ring atoms.
The invention also includes isotopically-labeled compounds, equivalent to those disclosed herein as the original compound. In practice, however, it will often occur that one or more atoms are replaced by an atom having a different atomic weight or mass number. Examples of isotopes that can be listed as compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, respectively 2 H、 3 H、 13 C、 11 C、 14 C、 15 N、 18 O、 17 O、 31 P、 32 P、 35 S、 18 F and 36 and (4) Cl. The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, wherein isotopes or other isotopic atoms containing those compounds are within the scope of the present invention. Certain isotopically-labelled compounds of the invention, e.g. 3 H and 14 Radioisotopes of C are also useful, among other things, in tissue distribution experiments of drugs and substrates. Tritium, i.e. 3 H and carbon-14, i.e. 14 C, their preparation and detection are relatively easy. Is the first choice among isotopes. In addition, heavier isotopes such as deuterium, i.e. 2 H, due to its good metabolic stability, may be advantageous in certain therapies, such as increased half-life in vivo or reduced dose, and therefore, may be preferred in certain circumstances. Isotopically-labeled compounds can be prepared by conventional methods by substituting a readily available isotopically-labeled reagent for a non-isotopically-labeled compoundThe reagents of (4) can be prepared using the protocols disclosed in the examples.
In the pharmaceutical composition, the weight ratio is calculated as the original compound of salvianolic acid and ginsenoside, unless otherwise specified.
"prevention" and "treatment" as used herein include delaying and stopping the progression of the disease, or eliminating the disease, and do not require 100% inhibition, elimination, or reversal. In some embodiments, the compositions or pharmaceutical compositions of the invention prevent, reduce, inhibit and/or reverse ischemia reperfusion injury, e.g., by at least about 10%, at least about 30%, at least about 50%, or at least about 80%, as compared to the levels observed in the absence of the compositions or pharmaceutical compositions of the invention.
A first active ingredient
In the present invention, the first active ingredient is selected from the group consisting of: salvianolic acid, its stereoisomers, its crystalline forms, its pharmaceutically acceptable salts or esters, or its derivatives, salvianolic acid-containing extracts, or combinations thereof.
In the present invention, the salvianolic acid can be selected from the following group:
salvianolic acid B (Salvianolic acid B, Sal B), Salvianolic acid A (Salvianolic acid A, Sal A), Salvianolic acid C (Salvianolic acid C, Sal C), iso-Sal C (Isosalvianolic acid C), Salvianolic acid D (Salvianolic acid D, Sal D), Salvianolic acid E (Salvianolic acid E, Sal E), Salvianolic acid F (Salvianolic acid F, Sal F), Salvianolic acid G (Salvianolic acid G, Sal G), Salvianolic acid H (Salvianolic acid H, Sal H), Salvianolic acid I (Salvianolic acid I, Sal I), Salvianolic acid J (Salvianolic acid J, Sal J), Salvianolic acid K (Salvianolic acid K, K), Salvianolic acid L (Salvianolic acid L, Sal L), Salvianolic acid L (Salvianolic acid M), Sal N (Sal M, Sal D E, Sal E, Sal E, Sal E, Sal E, Sal E, Sal E B, Sal E, Sal E B, Sal E B, Sal E, u), Salvianolic Acid Y (Salvinolic Acid Y, Sal Y), Caffeic Acid (Caffeic Acid), danshenu (Danshenu), Protocatechuic Acid (Protocatechuic Acid), protocatechualdehyde (Protocatechuic aldehyde), Ferulic Acid (Ferulic Acid), Isoferulic Acid (Isopterulic Acid), Salvinal ((CAS No. 135040-83-4), Ailanthionol (CAS No. 156398-61-7), Rosmarinic Acid (Rosmarinic Acid), Lithospermic Acid (Lithospermic Acid), salvianic Acid (salvianic Acid), salvianic Acid (Salvilasafetid), catechol (Catshihin), dimethyllithospermic Acid B (dimethyospermate B), tanshinone I (tanshinone I), dihydrotanshinone I, tanshinone A (tanshiniol-A), tanshinone IIA, tanshinone IIA (neotanshinone IIA), tanshinone I (neotanshinone I), neotanshinone (neotanshinone A), neotanshinone (neotanshinone I), or a combination thereof.
The specific structure of the above-mentioned danshensu is known to those skilled in the art (see, Chemical and pharmacological research on the polyphenolic acids isolated from Danshenn: A review of salvianoic acids. adv Pharmacol.2020; 87: 1-41; Salvia millirrhiza: A positional Red Light to the Development of Cardiosaccular diseases. Current Pharm Des.2017; 23(7): 1077-.
A second active ingredient
In the present invention, the second active ingredient is selected from the group consisting of: ginsenoside, its stereoisomer, its crystal form, its pharmaceutically acceptable salt or ester, or its derivative, ginsenoside-containing extract, or their combination.
In the present invention, the ginsenoside may be selected from the following group:
in another preferred embodiment, the ginsenoside is selected from the group consisting of: ginsenoside Re (Ginsenoside Re), Ginsenoside Rg1(Ginsenoside Rg1), Ginsenoside Rg2(Ginsenoside Rg2), Ginsenoside Rh1(Ginsenoside Rh1), Ginsenoside F1(Ginsenoside F1), Notoginsenoside R1 (Notogenoside R1), Notoginsenoside R1 (Notogenoside R1), Notoginsenoside M (Notogenoside M), Notoginsenoside N (Notogenoside N), Notoginsenoside Rt (Notogenoside Rt), Notoginsenoside T1 (Notogenoside T1), Notoginsenoside FP 72 (Notogenoside FP1), Notoginsenoside Rg Wo-1, Notoginsenoside Rg-Shisanoside R1, Notoginsenoside R3655 Wo 1, Notoginsenoside R1 (Notogenoside Rg-1), Notoginsenoside Rg Wo-Shisanoside R1, Notoginsenoside R1 (Notogenoside R1), Notoginsenoside R1, Notoginsenoside R3670 (Notogenoside R1), Ginsenoside R1, R3670, R1, R3670, R-R, R-R, R-R, R-R, R-R, R-R, R-R, R-R, R, Pseudoginsenoside RT3(Pseudoginsenoside RT3), saponin 10(saponin 10), saponin 1(saponin 1), saponin 2(saponin 2), saponin 3(saponin 3), Ginsenoside Ra3(Ginsenoside Ra3), Ginsenoside Rb1(Ginsenoside Rb1), Ginsenoside Rb2(Ginsenoside Rb2), Ginsenoside Rb3(Ginsenoside Rb 8), Ginsenoside Rc (Ginsenoside Rc), Ginsenoside Rd, Ginsenoside Rg3(Ginsenoside Rg3), Ginsenoside Rb1 (cinnamyl-Ginsenoside Rb1), Malonyl Ginsenoside Rd (Malonyl-Ginsenoside Rd), Ginsenoside Rd 3(6' -O-acenoside RT 4642), Ginsenoside Rg 584620 (Ginsenoside CK 4620) -Ginsenoside Rd 4620 (Ginsenoside Rd 3), Ginsenoside Rd (Ginsenoside Rd 4620), Ginsenoside Rd 4620 (Ginsenoside Rd) -Ginsenoside Rg3(Ginsenoside Rg 4623), Ginsenoside Rg 4620 (Ginsenoside Rg 4620) and Ginsenoside Rd (Ginsenoside Rg3), 20(R) -Ginsenoside Rh2(20(R) -Ginsenoside Rh2), 20(S) -Ginsenoside Rh2(20(S) -Ginsenoside Rh2), Notoginsenoside R4 (Notogenoside R4), Notoginsenoside K (Notogenoside K), gypenoside (Gypensoside XVII), gypenoside IX (Gypensoside IX), gypenoside XV (Gypensoside XV), gypenoside VIII (Gypensoside VIII), Notoginsenoside Fa (Notogenoside Fa), Notoginsenoside (Fc) Notogenoside Fc, Notoginsenoside Fe (Notogenoside Fe), Notoginsenoside D (Notogenoside D), Notoginsenoside L (Notogenide L), Notoginsenoside L (Notogenoside L), Notoginsenoside (Notogenoside Fnoside FP), Notoginsenoside (Notogenoside F2), Notoginsenoside Q (Notogenoside F) and Notoginsenoside Q (Notogenoside F) (Notogenoside FP), Notoginsenoside Q (Notogenoside Q) (Notogenoside F) (Notogenoside FP), Notoginsenoside Q (Notogenoside F) (Notogenoside FP), Notoginsenoside Q) (Notogenoside F) (I), Notoginsenoside F) (Notogenoside F) (Notogenin F) (Notogenide F) (I), notoginsen(Notogenoside F) (Notogenide F) (for the same, F) (for the same or the same) and F) (for the same of Notogenide F) (for the same of Notogenin) of Notogenin F) (for the same of Notogenin F) (for the same of Notogenin) of Notogenin the same of Notogenin F) (for the same of Notogenin the same of Not, Notoginsenoside ST-4 (Notogenoside ST-4), Notoginsenoside FZ (Notogenoside FZ), Notoginsenoside Fh1 (Notogenoside Fh1), or a combination thereof.
The specific structure of the above-mentioned ginsenosides is known to those skilled in the art (see, for example, Analytical methods and biological activities of Panax noggin, Recent tres. J. Ethnopharmacol.2019May23; 236: 443. 465.).
Pharmaceutical composition, combination and kit
(a) A first active ingredient selected from the group consisting of: salvianolic acid, a stereoisomer thereof, a crystalline form thereof, a pharmaceutically acceptable salt thereof, or an ester thereof, an extract containing salvianolic acid, or a combination thereof;
(b) a second active ingredient selected from the group consisting of: ginsenoside, its stereoisomer, its crystal form, its pharmaceutically acceptable salt, or its ester, ginsenoside-containing extract, or their combination; and
(c) a pharmaceutically acceptable carrier;
and the weight ratio of the first active ingredient to the second active ingredient is 1-100:100-1, wherein the weight ratio is calculated by salvianolic acid and ginsenoside compound.
Preferably, the weight ratio of the first active ingredient to the second active ingredient is 1-50:50-1, preferably 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5: (2-3.0).
The pharmaceutical composition of the present invention comprises the first active ingredient and/or the second active ingredient in a safe and effective amount range. Wherein "safe and effective amount" means: the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of the active ingredient/dose of the present invention, more preferably, 10-500mg of the active ingredient/dose of the present invention. Preferably, the "one dose" is a capsule, tablet, injection, etc.
In the present invention, the "pharmaceutically acceptable carrier" means: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with the first active ingredient and/or the second active ingredient without significantly diminishing the efficacy of the first active ingredient and/or the second active ingredient. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatinTalc, solid lubricants (such as stearic acid and magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil and olive oil), polyols (such as propylene glycol, glycerin, mannitol and sorbitol), and emulsifiers (such as 
) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The present invention also provides a combination of active ingredients comprising a combination of the first active ingredient and the second active ingredient as described above.
The invention also provides a kit comprising:
a pharmaceutical composition comprising a first active ingredient; and
a pharmaceutical composition comprising a second active ingredient.
In another preferred embodiment, the kit further comprises instructions.
In another preferred embodiment, the first and second pharmaceutical compositions are different (or separate) pharmaceutical compounds, or are the same pharmaceutical composition.
In another preferred embodiment, the first and second pharmaceutical compositions are administered simultaneously, separately or sequentially.
Use and method of administration
The present invention provides a use of a pharmaceutical composition, a combination of active ingredients or a kit as described herein for the preparation of a medicament or kit for (i) the prevention and/or treatment of ischemic diseases; (ii) prevention and/or treatment of ischemia reperfusion injury; and/or (iii) inhibits lactate dehydrogenase.
In the present invention, the ischemic disease refers to damage or lesion of a tissue or an organ due to ischemia. The term "ischemia" refers to a decrease in the blood supply to a tissue or organ from a normal level, and more particularly to a failure of the blood supply to meet the metabolic needs of the tissue or organ.
The active ingredients of the invention have obvious therapeutic effect on ischemic diseases. Common ischemic diseases include, but are not limited to: ischemic heart disease, ischemic stroke, ischemic liver injury, ischemic lung injury, ischemic kidney injury, or a combination thereof.
In the present invention, the ischemic heart disease is a heart disease caused by myocardial ischemia and hypoxia due to a change in coronary circulation. Common ischemic heart diseases include (but are not limited to) the following groups: coronary heart disease, myocardial infarction, myocardial fibrosis, angina pectoris, or a combination thereof.
In the present invention, the ischemia reperfusion injury includes tissue organ injury caused by reperfusion. The tissue organ includes (but is not limited to) the following groups: heart, liver, spleen, lung, kidney, brain, muscle, nerve, or combinations thereof. The tissue organ injury also includes post-operative reperfusion injury, the operation including (but not limited to) the following group: arterial bypass, thrombolytic therapy, percutaneous transluminal coronary angioplasty, cardiopulmonary and/or cerebral resuscitation after cardiac arrest, limb replacement or organ transplantation. The reperfusion injury further comprises: reperfusion injury after microcirculation dredging after shock and reperfusion injury after coronary artery spasm relieving.
In the present invention, the applications of the prevention and/or treatment of ischemic diseases, the prevention and/or treatment of ischemia-reperfusion injury, and the like include prophylactic applications and post-improvement applications. For example, for reperfusion injury, a pharmaceutical composition, composition of active ingredients or kit of parts of the invention is administered before, during, and/or after reperfusion to improve or enhance protection, repair or function of the tissue organ after reperfusion injury.
In the pharmaceutical compositions, combinations of active ingredients, or kits of the present invention, the first active ingredient and the second active ingredient may also be administered in combination with other pharmaceutically acceptable compounds, including (but not limited to): hypotensive agents, hypolipidemic agents, hypoglycemic agents, anti-platelet aggregation agents, and the like.
The pharmaceutical compositions, combinations or kits of active ingredients of the invention may also be used to inhibit lactate dehydrogenase. Lactate Dehydrogenase (LDH) is an enzyme required in the conversion of sugars into cellular energy, and is present in various organs and tissues throughout the body, for example: liver, heart, pancreas, kidney, skeletal muscle, lymphoid tissue, and blood cells. Lactate dehydrogenase is involved in the last step of glycolysis, where pyruvate is converted to lactate, and although normal tissues usually use glycolysis only when oxygen supply is insufficient, cancer tissues are heavily dependent on aerobic glycolysis, and LDH inhibitors are used in pathologies involving metabolic conversion from oxidative phosphorylation to glycolysis, for example, useful in (but not limited to): treating a patient suffering from cancer, fibrosis or other condition in which metabolic conversion from oxidative phosphorylation to glycolysis occurs. Meanwhile, lactate dehydrogenase is an enzyme responsible for converting glyoxylic acid into oxalic acid in a mitochondria/peroxisome glycine metabolic pathway of liver and pancreas, and the inhibition of LDH can be used for treating chronic kidney diseases such as hyperoxaluria. The pharmaceutical composition can reduce the LDH concentration in blood and/or inhibit the activity of LDH, and can be used as an LDH inhibitor.
In the pharmaceutical composition, combination of active ingredients or kit of the invention, the first active ingredient and the second active ingredient may be administered simultaneously, separately or sequentially at the time of administration.
In the pharmaceutical composition, combination of active ingredients or kit of the present invention, the administration mode of the first active ingredient and the second active ingredient is not particularly limited, and representative administration modes include (but are not limited to): oral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active ingredient is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active ingredient in such compositions may be delayed in a certain portion of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active ingredient may also be in microencapsulated form with one or more of the above excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, especially cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active ingredients, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms of the active ingredients of the present invention for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.
In the pharmaceutical composition, combination of active ingredients or kit of the invention, the therapeutically effective dose of the active ingredients will generally range from: about 1 to 2000 mg/day, about 10 to about 1000 mg/day, about 10 to about 500 mg/day, about 10 to about 250 mg/day, about 10 to about 100 mg/day, or about 10 to about 80 mg/day. A therapeutically effective dose will be administered in one or more doses. It will be understood, however, that the specific dose of the active ingredients of the invention for any particular patient will depend upon a variety of factors such as the age, sex, body weight, general health, diet, individual response, time of administration, severity of the condition to be treated, dosage form, mode of application and concomitant drug(s). A therapeutically effective amount for a given situation can be determined by routine experimentation and is within the abilities and judgment of a clinician or physician. In any event, the active ingredient will be administered in multiple doses based on the individual condition of the patient and in a manner that allows for the delivery of a therapeutically effective amount.
The main advantages of the invention include:
1. compared with the prior art, the pharmaceutical composition has better active ingredient proportion, and has better curative effect (such as excellent effects of reducing the infarct area and improving the functions of tissues and organs) on treating ischemic diseases and ischemia-reperfusion injury.
2. The medicine composition has the treatment effect on the reperfusion injury of the heart, different organs such as the brain, the liver, the lung, the kidney and the like, and can be widely applied to the ischemia reperfusion injury of various tissues and organs.
3. The pharmaceutical composition also has the effect of inhibiting lactate dehydrogenase, can quickly reduce the content and/or activity of the lactate dehydrogenase in blood, and can be used as a lactate dehydrogenase inhibitor for diseases related to the lactate dehydrogenase.
4. The compound of the invention has lower toxic and side effects, better pharmacodynamics, pharmacokinetic properties and druggability.
The invention is further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are by weight.
Reagents and materials
1.1 animals
134 male Wistar rats with the weight of 220 plus or minus 10g are cleaned;
wistar and SD rats are provided by Shanghai laboratory animal center of Chinese academy of sciences, raised in SPF animal room of Shanghai pharmaceutical research institute laboratory animal center of Chinese academy of sciences, kept at constant temperature of 22 + -2 deg.C for 12h, and fed with standard diet and free drinking water.
The administration mode comprises the following steps: the administration in the examples is tail vein injection, unless otherwise specified.
1.2 Main instruments
1.3 preparation of animal models
1.3.1 preparation of myocardial infarction model
Injecting pentobarbital sodium (40mg/kg) into abdominal cavity, fixing rat on chest hair on operation board, inserting pen-shaped venous indwelling needle sleeve into trachea to connect with animal respirator iodine tincture for disinfection, cutting skin blunt separation muscle between left 3-4 ribs of chest, opening gap between third rib and fourth rib and fixedly exposing upper part of heart, tearing off pericardium, holding 5-0 suture needle with thread by needle holder, using left coronary vein as mark, threading and ligating from 1mm position below junction of left auricle tip, pulmonary artery cone and auricle, and immediately turning myocardial tissue from ruddy to pale after ligation of coronary artery. The operation of the sham operated animal is the same except that the left anterior descending branch of the coronary artery is not ligated.
1.3.2 preparation of myocardial ischemia reperfusion injury model
Pentobarbital sodium (40mg/kg) was intraperitoneally injected, and the rats were fixed to an operating plate with the chest portion being hairy. Inserting a pen-shaped venous indwelling needle sleeve into a trachea to be connected with an animal respirator, disinfecting with iodine, cutting skin blunt separation muscles between 3-4 ribs on the left side of a chest, expanding the gap between the third rib and the fourth rib and fixedly exposing the upper part of a heart, tearing off a pericardium, clamping a 5-0 suture needle with a thread by a needle holder, threading the suture needle from the tip of a left auricle, the junction of the pulmonary artery cone and the auricle at a position of 1mm, placing a No. 2-0 thread at the knotted position of the two threads and ligating the suture needle, and immediately changing the myocardial tissue from ruddy to pale after the coronary artery is ligated. After 40 minutes of myocardial ischemia, the silk threads are cut open, the No. 2-0 line is taken out for myocardial ischemia reperfusion, and each detection and evaluation is carried out after 1 hour. The operation of the sham operated animal was identical except that the left anterior descending branch of the coronary artery was not ligated.
1.3.3 preparation of acute cerebral infarction model
After rat is anesthetized, fixed, breast hair and iodine tincture are disinfected, muscle, subcutaneous connective tissue, anterior cervical muscle group and exposed Common Carotid Artery (CCA) are sequentially separated; a small opening is cut at a position 4mm away from the bifurcation part of CCA, a plug wire is inserted into an Internal Carotid Artery (ICA) from the small opening, and the plug wire is pushed about 20mm from the bifurcation part of blood vessels, so that the Middle Cerebral Artery (MCA) is blocked to induce the generation of cerebral infarction.
1.3.4 preparation of cerebral ischemia reperfusion injury model
After rat is anesthetized, fixed, breast hair and iodine tincture are disinfected, muscle, subcutaneous connective tissue, anterior cervical muscle group and exposed Common Carotid Artery (CCA) are sequentially separated; a small opening is cut at a position 4mm away from a CCA bifurcation, a plug wire is inserted into an Internal Carotid Artery (ICA) from the small opening, the plug wire is pushed about 20mm from the bifurcation of a blood vessel, the Middle Cerebral Artery (MCA) is blocked for 2h to induce the generation of cerebral infarction, and the plug wire is pulled out after 2h to prepare a model of cerebral ischemia for 2h and reperfusion for 24 h. Administration was performed 10 minutes before removal of the wire plug (tail vein injection).
1.3.5 preparation of hepatic ischemia-reperfusion model
The preparation method of the model of the hepatic ischemia reperfusion injury comprises the following steps; weighing and anaesthetizing a rat, fixing the rat on an operating table and the abdominal hair; performing iodophor disinfection, and making a 5cm incision in the middle of the abdomen in the longitudinal direction to reach the xiphoid process; sequentially cutting skin, muscle and peritoneum to fully expose liver and gastrointestinal tract; separating the perihepatic ligament; clamping the middle lobe of the liver with a microscopic hemostatic clamp; exposing the left-leaflet portal vein, hepatic artery and bile duct; the color of liver lobe gradually changes from red to pale, which indicates the success of blocking the liver blood flow. Removing the hemostatic clamp after the blood flow is blocked for 1 h; the liver lobe color gradually becomes ruddy, suggesting successful liver reperfusion.
1.4 general Experimental methods
Separation and treatment of blood
Pentobarbital sodium (40mg/kg) anesthetic was injected intraperitoneally to anesthetized rats and fixed supine on a rat board. Cutting the abdomen with scissors along the median line, taking out the contents in the abdominal cavity, wiping the liquid in the abdominal cavity with a dry cotton ball, and taking blood from the abdominal aorta with a 5mL syringe into a 2mL EP tube; standing the blood on ice for 0.5 hr, centrifuging the collected blood at 4 deg.C and 8000r/min for 10min, collecting supernatant, subpackaging the serum in 0.5ml EP tube, and storing in refrigerator at-80 deg.C.
TTC dyeing
0.5g of TTC powder is dissolved in 100ml of PBS, and the solution is stored in the dark and prepared as it is. Cutting fresh tissue into multiple pieces, placing in a small box with a cover, adding TTC solution, placing in a wet box, keeping out of the sun, incubating in a constant temperature oven at 37 deg.C for 20min, turning over several times during the incubation period to make the tissue uniformly contact with the dye solution, taking out after 20min, and taking out for photographing.
Sample fixing, dehydrating, paraffin embedding and slicing
100mL of formaldehyde, 4g of sodium dihydrogen phosphate and 6.5g of disodium hydrogen phosphate are dissolved in 900mL of distilled water to prepare paraformaldehyde fixing liquid with the volume ratio of 10%. After the tissue is fixed in paraformaldehyde fixing solution for 72 hours, the tissue is washed by tap water for 2 hours, placed in a dehydrator for automatic dehydration according to a set program, and sequentially subjected to 75% ethanol for 1.5 hours, 95% ethanol for 1.5 hours, 100% ethanol for 1.5 hours, xylene for 1.5 hours and paraffin for 1.5 hours. The paraffin embedding machine is opened 2 hours in advance to melt paraffin, and the temperature is controlled at 60 ℃. After paraffin is melted, paraffin embedding is carried out on the dehydrated tissue, the dehydrated tissue is poured into an embedding box, the tissue block which is soaked in the paraffin is placed into an embedding frame by using a heated forceps, the tissue block is gently moved to a cold table, and after the paraffin is solidified, the paraffin block is taken down to prepare for slicing. Before slicing, the wax block is put into a refrigerator for precooling, and after cooling, the paraffin with the thickness of 5 mu m is sliced continuously by a slicer. The slices are spread on a spreading machine at 38 ℃ warm water, and the slices are fished out by a glass slide coated with polylysine and are naturally air-dried for subsequent histopathological staining.
HE staining
Placing the tissue slices on a 65 ℃ roasting machine, roasting for 60min, quickly placing xylene for dewaxing for 15min, sequentially soaking in 100%, 95% and 75% ethanol for 5min, flushing with running water for 5min, placing hematoxylin staining solution for 15min, flushing with water for 5min, then placing 1% hydrochloric acid ethanol differentiation solution (preparation: 3mL concentrated hydrochloric acid is added into 300mL 75% ethanol, and stirring uniformly) for 3s, returning the running water to blue for 5min, placing 1% eosin solution for 10min, quickly flushing off redundant eosin staining solution, then transferring to 75% ethanol for soaking for 4min, soaking in 95% ethanol for 4min, soaking in 100% ethanol for 5min, enabling the xylene to be transparent for 15min, finally sealing the slices with xylene neutral gum, after the gum is air-dried, taking a general picture by using a stereomicroscope, and taking a local enlarged picture by using a BX51 microscope.
PAS dyeing
Placing the tissue slices on a 65 ℃ chip baking machine, baking for 60min, quickly placing the tissue slices into xylene for dewaxing for 15min, sequentially soaking the tissue slices in 95%, 70% and 30% ethanol for 2min and distilled water for 2min, dropwise adding a prepared reagent application dye solution onto a sample of the slide to enable the sample to be completely covered, slightly and flatly placing the slide on a staining rack, and incubating for 8-15 min at room temperature in a dark place. The stained slide is taken out, and the slide is slowly washed for 3-5 minutes by running water. Before the slide is completely dried, the reagent II application liquid is dripped on the slide sample, the staining solution is uniformly blown by an ear washing ball and completely covers the sample, and then the slide is incubated at room temperature for 8 to 15 minutes. And after the incubation is finished, taking out the stained slide, slowly washing the slide for 30-60 seconds by running water, and naturally drying. And (3) dropwise adding a reagent III complex dye solution for dyeing for 20-30 seconds, then flushing with running water, sealing with a sealing agent after drying, taking a general picture by using a stereoscopic microscope after the sealing agent is dried in the air, and taking a local enlarged picture by using a BX51 microscope.
Biochemical index detection
LDH detection rat serum was detected using a fully automatic biochemical analyzer (JCA-BM6010/C, Hissemcon medical electronics (Shanghai) Co., Ltd.) according to a lactate dehydrogenase assay kit (lactate substrate method, Hissemcon Biotech (Wuxi) Co., Ltd., batch No.: R8004).
Haemodynamic testing
After rats were anesthetized by intraperitoneal injection of 40mg/kg pentobarbital sodium anesthetic, the right common carotid artery was isolated and a Miller catheter was inserted, and hemodynamic indices such as carotid artery pressure, left ventricular maximum contraction rate, left ventricular maximum relaxation rate, left ventricular end diastolic pressure, etc. were recorded using a Powerlab8/30 physiological recorder (ML870, ADINSTRUMENTES).
Calculation of left and right pulmonary indices
After weighing the rats, 30mg/kg of Shutai was intraperitoneally injected for anesthesia, and the left and right lungs were separated and weighed. And respectively calculating the left lung index and the right lung index according to the ratio of the left lung to the body weight to the right lung to the body weight.
Quantification of lung interstitial area
Quantitative analysis was performed on hematoxylin-eosin stained lung tissue. Each sample was taken at the same magnification to quantify the lung interstitial area, except for the lung parenchyma such as trachea, bronchi and alveoli, where the remaining purple portions represent the lung interstitium.
Immunohistochemical staining for neutrophil infiltration
Baking the paraffin-embedded tissues at 65 ℃ for 45-50 minutes; then xylene 15 minutes, absolute ethyl alcohol 5 minutes, 95% ethyl alcohol 5 minutes, 75% ethyl alcohol 3 minutes, flushing with running water for 1 minute, dewaxing to a water phase; under the microwave condition, repairing the antigen by using citric acid repairing liquid; incubating at 37 deg.C with 10% goat serum for 30 min; incubating CD44 antibody at 4 deg.C overnight; incubating the secondary antibody for 1 hour at 37 ℃; dripping DAB solution for 40 s; counterstaining with hematoxylin for 15 minutes; differentiating with 1% ethanol hydrochloride for 5 s; carrying out dimethylbenzene permeabilization; and (5) sealing the neutral gum. Positive cell area and optical density were quantified for each sample using Image Pro Plus software, and the mean optical density value was calculated as the ratio of optical density to positive cell area.
Behavioral testing of animals
Two days before and one day after surgery all experimental animals were subjected to Longa score, NSS score and EBST detection.
Longa scoring method: 0 minute: normal, no neurological impairment; 1 minute: the left forepaw can not be fully extended, and mild nerve function damage is caused; and 2, dividing: when walking, the rat turns to the left side (hemiparesis side), and moderate nerve function is damaged; and 3, dividing: when walking, the rat body topples to the left side (hemiparesis side), and the function of the nerve is seriously damaged; and 4, dividing: spontaneous walking is not possible and consciousness is lost.
Nss scoring method: 0 minute: the nerve function is normal; 1 minute: mild neurological deficit (left forelimb flexion when lifting the tail); and 2, dividing: moderate neurological deficit (circling to the left when walking); and 3, dividing: moderate neurological deficit (left slope); and 4, dividing: the consciousness is declined because the patient cannot walk; and 5, dividing: death associated with ischemia.
Elongated Body Swing Test: during measurement, the tail root of the rat is lifted by hands, the head of the rat is suspended about 5cm away from a plane, the head of the rat rotates leftwards or rightwards, the rotation angle to one side is greater than 100, the rotation direction and the rotation angle are recorded, the rat is allowed to rest for one minute after one test, the next test is carried out, the operation is repeated for 20 times, and the total direction and the total times are recorded.
Data statistical method
Data analysis was performed using GraphPad Prism 6.0(GraphPad software, LA Jolla, CA, usa), all measures were expressed as mean ± standard deviation, and homologies of variances were confirmed between means using One-way ANOVA. If the n values are consistent, comparing by adopting a Tukey method; if the n values are inconsistent, a Bonferroni method is adopted for comparison, and P < 0.05 has statistical significance.
Experiments prove that the pharmaceutical composition of the invention has more excellent effects in the aspects of treating ischemic diseases such as myocardial infarction, cerebral infarction, pulmonary embolism and the like and cardiac and cerebral ischemia-reperfusion injury (such as reducing infarct area and improving organ structure and function of tissues). Surprisingly, the pharmaceutical composition of the present invention also allows for a reduction in LDH concentration in blood and/or inhibits LDH activity, acting as an LDH inhibitor.
Because different tissues and organs (such as heart, liver, spleen, lung, kidney, brain, muscle, nerve and the like) have different tissue structures, functions, blood vessel distribution, requirements on blood and the like, whether the medicine has a treatment effect on ischemia perfusion injury of different organs or not is difficult to predict. Surprisingly, the pharmaceutical composition of the present invention exhibits excellent effects of improving organ functions not only for ischemia-reperfusion injury of the heart but also for ischemia-reperfusion injury of organs such as brain, kidney, liver, etc., and can be widely used for ischemia-reperfusion injury of various tissue organs.
More surprisingly, the salvianolic acid/ginsenoside combined medicine shows better treatment effect on ischemic diseases and ischemia-reperfusion injury of heart and brain than other tissues and organs, particularly has a surprising protection effect on ischemic stroke and reperfusion injury after ischemic stroke, not only obviously reduces the infarct area, but also obviously improves the behavior of animals, and indicates that the pharmaceutical composition has excellent treatment prospect on the heart diseases and the brain diseases.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (10)
1. A pharmaceutical composition, comprising:
(a) a first active ingredient selected from the group consisting of: salvianolic acid, its stereoisomer, its crystal form, its pharmaceutically acceptable salt or ester, or its derivative, extract containing salvianolic acid, or their combination;
(b) a second active ingredient selected from the group consisting of: ginsenoside, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, a ginsenoside-containing extract, or a combination thereof; and
(c) a pharmaceutically acceptable carrier;
and the weight ratio of the first active ingredient to the second active ingredient is 1-100:100-1, wherein the weight ratio is calculated by salvianolic acid and ginsenoside compound.
2. The pharmaceutical composition according to claim 1, wherein the weight ratio of the first active ingredient to the second active ingredient is 1-50:50-1, preferably 1-20:20-1, 1:10:10-1, 1-9:9-1, 1-8:8-1, 1-7:7-1, 1-6:6-1, 1-5:5-1, 1-4:4-1, 1-3:3-1, 1-2:2-1, 5 (1.5-3.5) or 5: (2-3.0).
3. The pharmaceutical composition of claim 1, wherein the salvianolic acid is selected from the group consisting of: salvianolic acid B (Salvianolic acid B, Sal B), Salvianolic acid A (Salvianolic acid A, Sal A), Salvianolic acid C (Salvianolic acid C, Sal C), iso-Sal C (Isosalvianolic acid C), Salvianolic acid D (Salvianolic acid D, Sal D), Salvianolic acid E (Salvianolic acid E, Sal E), Salvianolic acid F (Salvianolic acid F, Sal F), Salvianolic acid G (Salvianolic acid G, Sal G), Salvianolic acid H (Salvianolic acid H, Sal H), Salvianolic acid I (Salvianolic acid I, Sal I), Salvianolic acid J (Salvianolic acid J, Sal J), Salvianolic acid K (Salvianolic acid K, K), Salvianolic acid L (Salvianolic acid L, Sal L), Salvianolic acid L (Salvianolic acid M), Sal N (Sal M, Sal D E, Sal E, Sal E, Sal E, Sal E, Sal E, Sal E B, Sal E, Sal E B, Sal E B, Sal E, u), Salvianolic Acid Y (Salvianolic Acid Y, Sal Y), Caffeic Acid (Caffeic Acid), Danshensu (Danshensu), Protocatechuic Acid (protocatholic Acid), protocatechualdehyde (protocatholic aldehyde), Ferulic Acid (Ferulic Acid), Isoferulic Acid (Isoferulic Acid), Salvinal Acid, alanthodol, Rosmarinic Acid (Rosmarinic Acid), Lithospermic Acid (Lithospermic Acid), salvianic Acid (Lithospermic Acid), salvianoside (salvianoside), catechol (cathecol), dimethyllithospermidine b (dimethyllithotanshinone I), tanshinone I (tanshinone I), dihydrotanshinone I, salviandiol-a (salviandiol iia-a), tanshinone (tanshinone), cryptotanshinone (cryptotanshinone), neotanshinone (neotanshinone a), isotanshinone (isotanshinone a), or a combination thereof.
4. The pharmaceutical composition of claim 1, wherein the ginsenoside is selected from the group consisting of: ginsenoside Re (Ginsenoside Re), Ginsenoside Rg1(Ginsenoside Rg1), Ginsenoside Rg2(Ginsenoside Rg2), Ginsenoside Rh1(Ginsenoside Rh1), Ginsenoside F1(Ginsenoside F1), Notoginsenoside R1 (Notogenoside R1), Notoginsenoside R1 (Notogenoside R1), Notoginsenoside M (Notogenoside M), Notoginsenoside N (Notogenoside N), Notoginsenoside Rt (Notogenoside Rt), Notoginsenoside T1 (Notogenoside T1), Notoginsenoside FP 72 (Notogenoside FP1), Notoginsenoside Rg Wo-1, Notoginsenoside Rg-Shisanoside R1, Notoginsenoside R3655 Wo 1, Notoginsenoside R1 (Notogenoside Rg-1), Notoginsenoside Rg Wo-Shisanoside R1, Notoginsenoside R1 (Notogenoside R1), Notoginsenoside R1, Notoginsenoside R3670 (Notogenoside R1), Ginsenoside R1, R3670, R1, R3670, R-R, R-R, R-R, R-R, R-R, R-R, R-R, R-R, R, Pseudoginsenoside RT3(Pseudoginsenoside RT3), saponin 10(saponin 10), saponin 1(saponin 1), saponin 2(saponin 2), saponin 3(saponin 3), Ginsenoside Ra3(Ginsenoside Ra3), Ginsenoside Rb1(Ginsenoside Rb1), Ginsenoside Rb2(Ginsenoside Rb2), Ginsenoside Rb3(Ginsenoside Rb 8), Ginsenoside Rc (Ginsenoside Rc), Ginsenoside Rd, Ginsenoside Rg3(Ginsenoside Rg3), Ginsenoside Rb1 (cinnamyl-Ginsenoside Rb1), Malonyl Ginsenoside Rd (Malonyl-Ginsenoside Rd), Ginsenoside Rd 3 (6-O-acetyl-Rg 3), Ginsenoside Rg 4620 (Ginsenoside Rg3) -Ginsenoside Rd 584620 (Ginsenoside CK 4620), Ginsenoside Rd (Ginsenoside Rd 3), Ginsenoside Rd 4620 (Ginsenoside Rg3), Ginsenoside Rg3(Ginsenoside Rg 4623), Ginsenoside Rg3(Ginsenoside Rg 465) and Ginsenoside Rd, 20(R) -Ginsenoside Rh2(20(R) -Ginsenoside Rh2), 20(S) -Ginsenoside Rh2(20(S) -Ginsenoside Rh2), Notoginsenoside R4 (Notogenoside R4), Notoginsenoside K (Notogenoside K), gypenoside (Gypensoside XVII), gypenoside IX (Gypensoside IX), gypenoside XV (Gypensoside XV), gypenoside VIII (Gypensoside VIII), Notoginsenoside Fa (Notogenoside Fa), Notoginsenoside (Fc) Notogenoside Fc, Notoginsenoside Fe (Notogenoside Fe), Notoginsenoside D (Notogenoside D), Notoginsenoside L (Notogenide L), Notoginsenoside L (Notogenoside L), Notoginsenoside (Notogenoside Fnoside FP), Notoginsenoside (Notogenoside F2), Notoginsenoside Q (Notogenoside F) and Notoginsenoside Q (Notogenoside F) (Notogenoside FP), Notoginsenoside Q (Notogenoside Q) (Notogenoside F) (Notogenoside FP), Notoginsenoside Q (Notogenoside F) (Notogenoside FP), Notoginsenoside Q) (Notogenoside F) (I), Notoginsenoside F) (Notogenoside F) (Notogenin F) (Notogenide F) (I), notoginsen(Notogenoside F) (Notogenide F) (for the same, F) (for the same or the same) and F) (for the same of Notogenide F) (for the same of Notogenin) of Notogenin F) (for the same of Notogenin F) (for the same of Notogenin) of Notogenin the same of Notogenin F) (for the same of Notogenin the same of Not, Notoginsenoside ST-4 (Notogenoside ST-4), Notoginsenoside FZ (Notogenoside FZ), Notoginsenoside Fh1 (Notogenoside Fh1), or a combination thereof.
5. A combination of active ingredients, said combination of active ingredients comprising:
(a) a first active ingredient selected from the group consisting of: salvianolic acid, a stereoisomer, a crystalline form, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, an extract containing salvianolic acid, or a combination thereof;
(b) a second active ingredient selected from the group consisting of: ginsenoside, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, a ginsenoside-containing extract, or a combination thereof;
and the weight ratio of the first active ingredient to the second active ingredient is 1-100:100-1, wherein the weight ratio is calculated by salvianolic acid and ginsenoside compound.
6. A kit, comprising:
a first pharmaceutical composition comprising: (a) a first active ingredient selected from the group consisting of: salvianolic acid, its stereoisomer, its crystal form, its pharmaceutically acceptable salt or ester, or its derivative, extract containing salvianolic acid, or their combination; and a pharmaceutically acceptable carrier;
A second pharmaceutical composition comprising: (b) a second active ingredient selected from the group consisting of: ginsenoside, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt or ester thereof, or a derivative thereof, a ginsenoside-containing extract, or a combination thereof; and a pharmaceutically acceptable carrier;
and the first and second pharmaceutical compositions are administered in combination, wherein the weight ratio of the first and second active ingredients is 1-100:100-1, wherein the weight ratio is based on salvianolic acid and ginsenoside compounds.
7. The pharmaceutical composition according to one aspect, the combination of active ingredients according to the second aspect of the invention, or the use of the kit according to the third aspect of the invention, for the preparation of a medicament or kit for (i) the prevention and/or treatment of ischemic diseases; (ii) prevention and/or treatment of ischemia reperfusion injury; (iii) inhibit lactate dehydrogenase.
8. The use according to claim 7, wherein the ischemic disease is selected from the group consisting of: ischemic injury of tissues and organs due to primary lesions of tissues and blood vessels, and/or ischemic lesions due to secondary causes, such as blood vessel detachment due to trauma, blood supply loss during organ transplantation, blood vessel occlusion due to inflammation, and blood vessel compression due to tumors.
9. The use according to claim 7, wherein the ischemic disease is selected from the group consisting of: ischemic heart disease, ischemic stroke (such as acute cerebral infarction), ischemic liver injury, pulmonary embolism, ischemic kidney injury, ischemic nerve injury, or a combination thereof.
10. The use of claim 9, wherein the ischemic heart disease comprises: coronary heart disease, myocardial infarction, angina pectoris, myocardial fibrosis, heart failure, or a combination thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110215334.0A CN114948978A (en) | 2021-02-25 | 2021-02-25 | Pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110215334.0A CN114948978A (en) | 2021-02-25 | 2021-02-25 | Pharmaceutical composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114948978A true CN114948978A (en) | 2022-08-30 |
Family
ID=82972701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110215334.0A Pending CN114948978A (en) | 2021-02-25 | 2021-02-25 | Pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114948978A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925662A (en) * | 2022-09-21 | 2023-04-07 | 台州永健医药科技有限公司 | Novel crystal form of salvianolic acid C and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985836A (en) * | 2006-12-18 | 2007-06-27 | 贵州信邦远东药业有限公司 | Medicine composition for treating cerebral ischemia |
| CN102908355A (en) * | 2011-08-04 | 2013-02-06 | 中国科学院上海药物研究所 | Medicinal composition and application thereof |
| CN112438973A (en) * | 2019-08-29 | 2021-03-05 | 中国科学院上海药物研究所 | Pharmaceutical composition and application thereof |
-
2021
- 2021-02-25 CN CN202110215334.0A patent/CN114948978A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985836A (en) * | 2006-12-18 | 2007-06-27 | 贵州信邦远东药业有限公司 | Medicine composition for treating cerebral ischemia |
| CN102908355A (en) * | 2011-08-04 | 2013-02-06 | 中国科学院上海药物研究所 | Medicinal composition and application thereof |
| CN112438973A (en) * | 2019-08-29 | 2021-03-05 | 中国科学院上海药物研究所 | Pharmaceutical composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李强，夏晓晖: "《新编常用中药有效成分手册》", 中国协和医科大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925662A (en) * | 2022-09-21 | 2023-04-07 | 台州永健医药科技有限公司 | Novel crystal form of salvianolic acid C and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2614700C (en) | Medicinal composition containing ginseng secondary glycosides, its preparation method and application | |
| CA2538478C (en) | A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| CN112438973A (en) | Pharmaceutical composition and application thereof | |
| WO2017041711A1 (en) | The use of kauranes compounds in the manufacture of medicament for treatment of cardiac hypertropy and pulmonary hypertension | |
| CN102526186A (en) | Medicinal composition for preventing and treating cardiovascular diseases and application thereof | |
| CN114948978A (en) | Pharmaceutical composition and application thereof | |
| CN106344648B (en) | Thymus plant, extract and application thereof | |
| EP4043012A1 (en) | Drug for treating artery-related diseases, and use thereof | |
| KR100327894B1 (en) | Hypertension-treatment and colestearol-depressant composition comprising extract from mixture of panax notoginseng and salvia miltiorrhiza and method of preparing the same | |
| JP5671524B2 (en) | Pharmaceutical composition for the treatment of cardiovascular disorders and use thereof | |
| US6589572B2 (en) | Hypertension-treatment and cholesterol-depressant composition comprising extract from mixture of Panax notoginseng and Salvia miltiorrhiza and method of preparing the same | |
| Léandre et al. | Effects of leaf decoction from Lophira lanceolata Tiegh. Ex Keay (Ochnaceae) on arterial blood pressure and electrocardiogram in anesthetized rabbits | |
| ZA200603160B (en) | Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders | |
| CN104027525A (en) | Drug for treatment of ischemic heart disease, preparation method and application thereof | |
| CN113750085A (en) | Application of natural compound and derivative thereof in treating arterial lesion | |
| CN104435067B (en) | A kind of Cortex Eucommiae components composition and preparation thereof with myocardium protecting action | |
| CN112263624B (en) | Application of Ningxia wolfberry extract and wolfberry polysaccharide in preparing medicines for preventing and treating heart fibrosis | |
| CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof | |
| WO2023143633A2 (en) | Salvianolic acid a sodium salt hydrate and preparation method therefor | |
| Wang et al. | Effects of ginsenoside Rb1 on serum brain natriuretic peptide level and caspase-3 protein expression in cardiomyocytes of rats with chronic heart failure | |
| CN117899176A (en) | Chinese medicinal composition for treating coronary heart disease and angina pectoris and preparation method thereof | |
| CN117462627A (en) | Preparation method and application of composition targeting intestinal flora-UCP 1 axis | |
| CN112274557A (en) | Rabdosia rubescens leaf water extract powder, preparation method thereof, anti-arterial thrombosis effect and application thereof | |
| CN118045097A (en) | Traditional Chinese medicine component composition for preventing and treating pulmonary fibrosis and application thereof | |
| WO2014015507A1 (en) | Application of shengui capsule in preparing antithrombotic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220830 |
|
| WD01 | Invention patent application deemed withdrawn after publication |